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tor) to the C-terminus of the Aa chains in vivo, has been 
shown to be a reproducible method of crosslinking RGD-
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SPONSORED RESEARCH OR DEVELOPMENT 
10 J Control Release 2005, 101(1-3):93-109; Schmoekel HG, et 
al. Biotechnol Bioeng 2005, 89(3):253-262; Pittier R, et al. J 
Neurobiol 2005, 63(1):1-14; Arrighi I, et al. Biomaterials 
2009, 30(9):1763-0.1771; Hall H, et al. Microvasc Res 2004, 
This invention was made with Government Support under 
Agreement 1R21EB008463 and K12 GM000680 by the 15 
National Institutes of Health. The Government has certain 
rights in the invention. 
REFERENCE TO SEQUENCE LISTING 
68(3):169-178). As an intriguing spin-off, bi-domain pep-
tides comprising the factor XIIIa substrate sequence and the 
heparin-binding domain have been used to increase the con-
centration of fibrin-bound heparin, thereby improving the 
retention characteristics of heparin-binding growth factors 
(Willerth SM, et al. J Biomed Mater Res A 2007, 80(1):13-
The Sequence Listing submitted Jul. 9, 2010, as a text file 
named "GTRC_ 4021_ST25.txt," created on Jul. 7, 2010, and 
having a size of 6,764 bytes is hereby incorporated by refer-
ence. 
20 23; Wood MD, et al. J Biomed Mater Res A 2008, 84(2):300-
312; Sakiyama-Elbert S E, et al. J Control Release 2000, 
65(3):389-402; Sakiyama-Elbert SE, et al. J Control Release 
2000, 69(1):149-158). In particular, such biomimetic affinity-
based systems are advantageous for the local delivery of 
FIELD OF THE INVENTION 
The invention is generally related to peptides and fusion 
proteins and their use for incorporating substances into fibrin 
polymers. 
25 factors that are internalized by cells as part of the signaling 
process. These methods, however, require intermediary mol-
ecules or enzymes, like factor XIIIa, to conjugate the agents 
to fibrin, and the desired deliverable, such as a drug or protein, 
30 
BACKGROUND OF THE INVENTION 
can not be incorporated prior to the initiation of polymer. 
It is an object of the invention to provide improved methods 
of incorporating therapeutic agents into a fibrin polymer. 
It is a further object of the invention to target substances to 
fibrinogen and fibrin within a subject. 
Fibrin, formed in response to vascular injury, constitutes 
the protein polymeric scaffold known as the provisional 
extracellular matrix. Fibrin serves as the temporary initial 
scaffolding for the invasion of inflammatory and repair cells 
into wound environments. Fibrinogen, the inactive precursor 
It is a further object of the invention to provide methods for 
35 detecting fibrin polymers in a subject. 
to fibrin, is a 340 kDa plasma glycoprotein that circulates in 
blood plasma at concentrations of 2 to 4 mg/mL. As a part of 40 
its normal functions, fibrin( ogen) features a variety ofbinding 
sites for self-regulatory enzymes (including thrombin, factor 
XIII, plasminogen, tissue plasminogen activator), ECM com-
ponents, growth factors, cytokines and cell receptors; com-
ponents that are critical in the remodeling of the matrix as part 45 
of the wound healing response (Laurens N, et al. J Thromb 
Haemost 2006, 4(5):932-939; Mosesson M W. J Thromb 
Haemost 2005, 3(8):1894-1904). Due to the ease of purifica-
tion of this highly expressed plasma protein and its native role 
in the guidance of wound repair, the fibrinogen/fibrin system 50 
is employed in a number of surgical hemostats and tissue 
sealants (FDA-approved products include Tisseel®, 
Evicel™) and is actively used as a biomaterial for developing 
therapeutic strategies in regenerative medicine (Spotnitz W 
D, et al. Transfusion 2008; 48(7):1502-1516; Ahmed TA, et 55 
al. Tissue Eng PartB Rev 2008, 14(2): 199-215; BreenA, eta!. 
Tissue Eng Part B Rev 2009, 15(2): 201-214). 
Significant efforts have been made to develop and enhance 
fibrin as a tissue scaffold and drug delivery vehicle through 
both modification of the molecule and engagement of the 60 
native polymer system biology. For instance, functionalized 
polyethylene glycol was explored as a means to covalently 
tether therapeutic proteins to fibrinogen's backbone thus 
enabling their delivery in fibrin polymers (Barker TH, et al. J 
Biomed Mater Res 2001, 56( 4):529-535). Alternatively, fac- 65 
tor XIIIa, also responsible for the covalent attachment of 
other non-fibrin proteins (e.g. fibronectin, a2-plasmin inhibi-
It is a further object of the invention to promote wound 
healing in a subject. 
It is a further object of the invention to provide fibrin 
polymers with modified physical properties. 
SUMMARY OF THE INVENTION 
In accordance with the purpose of this invention, as embod-
ied and broadly described herein, this invention relates to 
compositions and methods for targeting substances to 
fibrinogen, fibrin monomers, or fibrin polymers. These com-
positions and methods generally involve the use of fibrin knob 
peptides that bind fibrin(ogen), which can be used to detect 
fibrin(ogen) and modulate fibrin polymerization and fibrin-
olysis. 
Isolated polypeptides are provided that include fibrin 
knobs at the N-terminus of the polypeptide, wherein the iso-
lated polypeptide binds fibrin. Recombinant fusion proteins 
are also provided that contain a fibrin knob peptide at the 
N-terminus of the fusion protein and therefore bind fibrin. 
The recombinant fusion proteins can contain any polypeptide 
suitable to target to fibrin(ogen). In some embodiments, the 
fusion proteins include a bioactive polypeptide that promotes 
wound healing or fibrinolysis. In some embodiments, the 
fusion protein contains or is conjugated to an inert protein that 
sterically hinders fibrin polymerization when the fusion pro-
tein binds fibrin. 
Methods of targeting agents to fibrin(ogen) within a sub-
ject are also provided, involving administering to the subject 
a pharmaceutical composition comprising a fibrin knob pep-
tide conjugated to the agent. The agent can be any molecule, 
protein, polymer, nucleic acid, or the like that is suitable for 
US 8,513,380 B2 
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administration to a subject and for targeting to fibrin(ogen). 
For example, the agent can be a detectable label, a bioactive 
polypeptide that promotes wound healing or fibrinolysis, or 
an inert protein or polymer that hinders fibrin polymerization 
when the fusion protein binds fibrin. Therefore, methods are 5 
provided for diagnosing or treating diseases in a subject that 
involve fibrin overproduction, such as pulmonary fibrosis and 
fibrin clots. 
FnIII9_10 (SEQ ID NO:ll, square). FIG. 4B is a line graph 
from ELISA studies showing affinity of fusion proteins for 
fibrinogen (percent signal at Abs450 nm normalized against 
signal obtained in the presence of the non-binding GSPE 
(SEQ ID NO: 11) peptide) as a function of peptide concentra-
tion (µg/ml) for GPRP (SEQ ID NO:l, closed circle), GPRV 
(SEQ ID N0:2, open circle), GHRP (SEQ ID N0:3, open 
square), and GSPE (SEQ ID NO: 11, closed square). 
Methods of treating a wound in a subject are also provided 
that involve simultaneously administering to the wound a first 
pharmaceutical composition and second pharmaceutical 
composition, wherein the first pharmaceutical composition 
comprises a fibrin knob peptide conjugated to an agent, 
wherein the second pharmaceutical composition comprises 
thrombin. In these methods, the agent conjugated to the fibrin 
knob peptide preferably promotes healing, promotes fibrin-
olysis, or sterically hinders fibrin polymerization 
Additional advantages of the disclosed composition(s) and 
method(s) will be set forth in part in the description which 
follows, and in part will be understood from the description, 
FIGS. SA and SB are line graphs showing turbidity as a 
10 function of time (min) for clots formed from 6 µM (=2 
mg/mL) fibrinogen solutions containing 0.6 µM control 
(solid line), GPRP-FnIII9_10-biotin (SEQ ID NO:l, dashed 
line) and GSPE-FnIII9_10-biotin (SEQ ID NO:ll, dash-dot 
line) fusion proteins upon the addition of 1 U/mL factor XIIIa 
15 and 1 U/mL human a-thrombin (FIG. SA) or batroxobin 
moojeni (FIG. SB). FIG. SC is a bar graph showing complex 
modulus (Pa) of the clots after 30 min clotting time using 
control (first and fourth bars), GPRP-FnIII9_10 (SEQ ID 
NO:l, second and fifth bars), and GSPE-FnIII9_10 (SEQ ID 
20 NO: 11, third and sixth bars). FIG. SD is a bar graph showing 
soluble protein (ng/ml) in the clot liquor from clots after 1 
hour clotting time using control (first and fourth bars), GPRP-
FnIII9_10 (SEQ ID NO:l, second and fifth bars), and GSPE-
or may be learned by practice of the disclosed composition(s) 
and method(s). The advantages of the disclosed 
composition( s) and method( s) will be realized and attained by 
means of the elements and combinations particularly pointed 
out in the appended claims. It is to be understood that both the 25 
foregoing general description and the following detailed 
description are exemplary and explanatory only and are not 
restrictive of the invention as claimed. 
FnIII9_10 (SEQ ID NO:l 1, third and sixth bars). 
FIGS. 6A and 6C are bar graphs showing FnIII9_10 release 
(ng) at 1 hour (1st set ofbars ), 4 hours (2nd set of bars), 8 hours 
(3rd set of bars), 12 hours (4th set of bars), 24 hours (5th set of 
bars), 48 hours (6th set of bars), 72 hours (7th set of bars), and 
96 hours (8th set of bars) using GPRP-FnIII9_10 (SEQ ID 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG.1 is a schematic showing fibrinogen and its activation. 
The activation offibrinogen (top) by thrombin exposes fibrin 
knobs in the NDSK domain that bind to complementary 
pockets in the D domain of the molecule (middle). Such 
knob:pocket interactions are key in the assembly of fibrin 
protofibrils (bottom) in fibrin network formation. 
FIG. 2 is an illustration of a cloning method for molecular 
engineering of the pGEX4 T-1 vector to express proteins with 
variable thrombin cleavage sites, which allow for the presen-
tation of the knob sequence at the N-terminus following 
thrombin treatment. Site-directed mutagenesis was used to 
modify the coding sequence for the thrombin cleavage site 
(T) (SEQ ID NOs:33-36). Next, the open reading frame of the 
protein-of-interest, FnIII9_10, was inserted into the multiple 
cloning site (MCS). The expressed proteins comprise an 
N-terminal glutathione S-transferase (GST) tag, followed by 
the thrombin cleavage site and protein-of-interest. 
FIG. 3A is a surface plasmon resonance (SPR) line-graph 
showing protein-protein affinity (1 RU=l pg/mm2 ) of fusion 
proteins for immobilized fibrinogen fragment Das a function 
30 NO:l, closed bars), and GSPE-FnIII9_10 (SEQ ID NO:ll, 
open bars) fusion proteins upon the addition of 1 U/mL factor 
XIIIa and 1 U/mL human a-thrombin (FIG. 6A) or batrox-
obin moojeni (FIG. 6C). FIGS. 6B and 6D are line graphs 
showing percent cumulative release as a function of time 
35 (v'h05 ) using GPRP-FnIII9_10 (SEQ ID NO:l, circles), and 
GSPE-FnIII9_10 (SEQ ID NO: 11, squares) fusion proteins 
upon the addition of 1 U/mL factor XIIIa and 1 U/mL human 
a-thrombin (FIG. 6B) or batroxobin moojeni (FIG. 6D). 
FIGS. 7 A and 7C are bar graphs showing FnIII9_10 release 
40 (ng) at 1 hour (1st set ofbars ), 4 hours (2nd set of bars), 8 hours 
(3rd set of bars), 12 hours (4th set of bars), 24 hours (5th set of 
bars), 48 hours (6th set of bars), 72 hours (7th set of bars), and 
96 hours (8th set of bars) using GPRP-FnIII9_10 (SEQ ID 
NO:l, FIG. 7A)orGSPE-FnIII9_10 (SEQIDNO:l1, FIG. 7C) 
45 fusion proteins upon the addition of 1 U/mL factor XIIIa and 
1 U/mL human a-thrombin (closed bars) or batroxobin 
moojeni (open bars). FIGS. 7B and 6D are line graphs show-
ing percent cumulative release as a function of time (v'h0 ·5 ) 
using GPRP-FnIII9_10 (SEQ ID NO:l, FIG. 7B) or GSPE-
50 FnIII9_10 (SEQ ID NO: 11, FIG. 7D) fusion proteins upon the 
addition of 1 U/mL factor XIIIa and 1 U/mL human a-throm-
of time (s) for 50 µM (top line) and 10 µM (middle line) 
GPRP-FnIII9_10 (SEQ ID NO: 1) and 10 µMand 50 µM (bot-
tom lines) GSPE-FnIII9_10 (SEQ ID NO:l 1). FIG. 3B is a SPR 
line-graph showing protein-protein affinity (1 RU=l 55 
pg/mm2 ) of fusion proteins for immobilized fibrinogen frag-
ment Das a function of concentration (M) for GSPE-FnIII9_10 
(SEQ ID NO:ll, open circle), GPRP-FnIII9_10 (SEQ ID 
NO:l, triangle), GPRV-FnIII9_10 (SEQ ID N0:2, open 
square), GHRP-FnIII9_10 (SEQ ID N0:3, closed square), and 60 
GPRP-FnIII9_10 (SEQ ID NO: 1 )+GPRP (SEQ ID NO: 1, "x"). 
bin (circle) or batroxobin moojeni (square). 
FIG. SA is a schematic representation of fibrinogen and the 
two major regions, E and D. Plasmin treated fibrinogen and 
purification of the fragments generates fragment D. FIG. SB 
is a schematic representation of the SPR experimental set-up 
with fragment D immobilized to an SPR chip acting as the 
ligand and the knob 'A' peptides flow across the surface as the 
analyte. FIG. SC is a representative SPR line-graph showing 
protein-protein affinity (RU) of fusion proteins for immobi-
lized fibrinogen fragment Das a function of time ( s) where the 
carboxyl-terminated SAMs were activated by EDC/NHS 
enabling amine-targeted immobilization of fragment D. 
Ethanolamine quenched any unreacted carboxyl groups and 
rid the surface of non-specifically bound fragment D. 
FIG. 4A is a line graph from ELISA studies showing affin-
ity of fusion proteins for fibrinogen (percent signal atAbs450 
nm normalized against maximum signal obtained using 
GPRPFPAC (SEQ ID N0:5) at coating concentration of 20 65 
µg/ml) as a function offibrinogen coating concentration (µg/ 
ml) for GPRP-FnIII9_10 (SEQ ID NO:l, circle) and GSPE-
FIGS. 9A and 9B are SPR line-graph showing protein-
protein affinity (RU) of GPRPFPAC (SEQ ID N0:5) for 
US 8,513,380 B2 
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immobilized fibrinogen fragment Das a function of time (s) 
fitted with Langmuir 1: 1 model (FIG. 9A) or heterogeneous 
ligand model (FIG. 9B). FIGS. 9C and 9D are residual plots 
corresponding to the Langmuir 1 : 1 model (FIG. 9C) or het-
erogeneous ligand model (FIG. 9D). Solid 5 
lines=experimental SPR response curves, dashed lines=fitted 
model curves. 
FIG. lOA is a simulated SPR line-graph generated by the 
heterogeneous ligand model for GPRPFPAC (SEQ ID NO: 5). 
The combine response (solid line) is a sum of analyte-ligand 10 
complexes AB (dashed line) andAB* (dash-dot line). FIG. 
1 OB is an SPR line-graph showing Maximal binding response 
(RU) ofGPSPAAC (SEQ ID N0:9, "+"), GPRPAAC (SEQ 
ID N0:4, open circle), GPRPFPAC (SEQ ID N0:5, "x"), 
GPRPPERC (SEQ ID N0:6, closed square), GPRVVERC 15 
(SEQ ID N0:7, open square), and GPRVVAAC (SEQ ID 
NO:S, diamond) for immobilized fibrinogen fragment Das a 
function of peptide concentration (M). 
FIGS. HA-HJ are SPR line-graphs (HA, HC, HE, HG, 
and HI) and residual plots (HB, HD, HF, HH, and HJ) 20 
showing protein-protein affinity (RU) ofGPRPAAC (SEQ ID 
N0:4, FIGS. HA and HB), GPRPFPAC (SEQ ID N0:5, 
FIGS. HCandHD), GPRPPERC(SEQIDN0:6, FIGS. HE 
and HF), GPRVVERC (SEQ ID N0:7, FIGS. HG and HH), 
and GPRVVAAC (SEQ ID NO:S, FIGS. HI and HJ) for 25 
immobilized fibrinogen fragment Das a function of time (s) 
fitted with Langmuir 1: 1 model. Solid lines=experimental 
SPR response curves, dashed lines=fitted model curves. 
FIGS. 12A-12J are SPR line-graphs (12A, 12C, 12E, 12G, 
and 12I) and residual plots (12B, 12D, 12F, 12H, and 12J) 30 
showing protein-protein affinity (RU) ofGPRPAAC (SEQ ID 
N0:4, FIGS. 12A and 12B), GPRPFPAC (SEQ ID N0:5, 
FIGS.12C and 12D), GPRPPERC (SEQ ID N0:6, FIGS.12E 
and 12F), GPRVVERC (SEQ ID N0:7, FIGS. 12G and 12H), 
and GPRVVAAC (SEQ ID NO:S, FIGS. 12I and 12J) for 35 
immobilized fibrinogen fragment Das a function of time (s) 
fitted with heterogenous ligand model. Solid 
lines=experimental SPR response curves, dashed lines=fitted 
model curves. 
FIGS. 13A-E are dendrograms from hierarchical cluster 40 
analysis from a dissimilarity matrix generated from the Root 
mean squared deviation (RMSD) between every frame in the 
trajectory for GPRPFPAC (SEQ ID N0:5, FIG. 13A), GPRV-
VAAC (FIG. 13B, SEQ ID NO:S), GPRPAAC (SEQ ID 
N0:4, FIG. 13C), GPRPPERC (SEQ ID N0:6, FIG. 13D), 45 
and GPRVVERC (SEQ ID N0:7, FIG. 13E). 
FIG.14 is a bar graph showing peptide:PEG molar ratio for 
GPRP (SEQ ID NO: 1, left bars) and GPSP (SEQ ID NO: 19, 
right bars) conjugated with three varieties of PEG (MAL-
PEG (first set of bars), MAL2 -PEG (second set of bars), and 50 
MAL4 -PEG (third set of bars)). The "expected" ratio is shown 
superimposed on the actual ratios obtained. 
FIG. 15A is a line graph showing percent change in fibrin 
turbidity as a function of time (minutes) for thrombin-in-
duced fibrin polymerization in the presence of a 10: 1 molar 55 
ratio ofGPRP-PEG (SEQ ID NO:l) conjugate to fibrinogen, 
GPRP (SEQ ID NO:l) peptide, PEG, or buffer only. FIGS. 
15B and 15C are line graphs showing percent change in fibrin 
turbidity as a function of time (minutes) in the presence of a 
10:1 molar ratio to fibrinogen of knob-PEG conjugates 60 
GPRP1-PEG (SEQ ID NO:l), GPRP2 -PEG (SEQ ID NO:l) 
and GPRP4 -PEG (SEQ ID NO:l) (FIG. 15B) followed by 
thrombin-induced polymerization (FIG. 15C). 
FIG. 16A is a line graph showing turbidity at 350 nm as a 
function of time (minutes) after control (bottom line) or 65 
thrombin-induced polymerization with no peptide (top line), 
GPSPFPAC-PEG (SEQ ID N0:18, second line from top) or 
6 
GPRPFPAC-PEG (SEQ ID N0:5, third line from the top). 
FIG. 16B is a bar graph showing percent clottability after 
thrombin-induced polymerization with no peptide (first bar), 
GPSPFPAC-PEG (SEQ ID NO: 18, second and fourth bar) or 
GPRPFPAC-PEG (SEQ ID N0:5, third and fifth 
bar). *=p<0.01 relative to all groups. 
FIG. 17 is a bar graph showing percent clottable protein 
measured via protein assay after 1 hr of thrombin-induced 
polymerization in presence or absence of no peptide (first 
bar), or the fibrin knob peptides GPSPAAC (2nd and 6th bars, 
SEQ ID N0:9), GPRPFPAC (3rd and 7th bars, SEQ ID N0:5), 
GPRPPERC (4th and gth bars, SEQ ID N0:6), or GPRPAAC 
(4th and gth bars, SEQ ID N0:4). *p<0.05, $ p<0.01 compared 
to all groups. 
DETAILED DESCRIPTION OF THE INVENTION 
Compositions and methods are provided for integrating 
substances, such as bioactive agents or inert polymers, into 
fibrin. This process takes advantage of the native knob:pocket 
interactions involved in fibrinogen assembly into fibrin poly-
mers. 
I. DEFINITIONS 
Unless otherwise noted, technical terms are used according 
to conventional usage. Definitions of common terms in 
molecular biology may be found in Lewin, Genes VII, pub-
lished by Oxford University Press, 2000; Kendrew et al. 
(eds.), The Encyclopedia of Molecular Biology, published by 
Wiley-Interscience, 1999; and Robert A. Meyers (ed.), 
Molecular Biology and Biotechnology, a Comprehensive 
Desk Reference, published by VCH Publishers, Inc., 1995; 
Sambrook and Russell. (2001) Molecular Cloning: A Labo-
ratory Manual 3rd. edition, Cold Spring Harbor Laboratory 
Press. 
To facilitate understanding of the disclosure, the following 
definitions are provided: 
The term "amino acid sequence" refers to a list of abbre-
viations, letters, characters or words representing amino acid 
residues. The amino acid abbreviations used herein are con-
ventional one letter codes for the amino acids and are 
expressed as follows: A, alanine; B, asparagine or aspartic 
acid; C, cysteine; D aspartic acid; E, glutamate, glutamic 
acid; F, phenylalanine; G, glycine; H histidine; I isoleucine; 
K, lysine; L, leucine; M, methionine; N, asparagine; P, pra-
line; Q, glutamine; R, arginine; S, serine; T, threonine; V, 
valine; W, tryptophan; Y, tyrosine; Z, glutamine or glutamic 
acid. Conservative substitutions and deletions are described 
below. 
The term "residue" or "position," with respect to an amino 
acid residue in a polypeptide, refers to a number correspond-
ing to the numerical place that residue holds in the polypep-
tide. By convention, residues are counted from the amino 
terminus to the carboxyl terminus of the polypeptide. Thus, 
position 326 ofhuman eNOS would be the 326th residue from 
the amino terminus of the eNOS protein sequence. 
The term "nucleic acid" refers to a natural or synthetic 
molecule having a single nucleotide or two or more nucle-
otides linked by a phosphate group at the 3' position of one 
nucleotide to the 5' end of another nucleotide. The nucleic 
acid is not limited by length, and thus the nucleic acid can 
include deoxyribonucleic acid (DNA) or ribonucleic acid 
(RNA). 
An "isolated" nucleic acid molecule or polynucleotide is a 
nucleic acid molecule that is identified and separated from at 
least one substance with which it is ordinarily associated in 
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the natural source. The isolated nucleic can be, for example, 
free of association with all components with which it is natu-
rally associated. An isolated nucleic acid molecule is other 
than in the form or setting in which it is found in nature. 
The term "vector" refers to a nucleic acid sequence capable 
of transporting into a cell another nucleic acid to which the 
vector sequence has been linked. The vectors can be expres-
sion vectors. 
The term "expression vector" refers to a vector that 
includes one or more expression control sequences. 
8 
where W is the number of nucleotides or amino acids scored 
as identical matches by the sequence alignment program in 
that program's alignment of C and D, and where Z is the total 
number of nucleotides or amino acids in D. It will be appre-
ciated that where the length of sequence C is not equal to the 
length of sequence D, the % sequence identity of C to D will 
not equal the % sequence identity of D to C. 
As used herein, the term "nucleic acid" may be used to refer 
to a natural or synthetic molecule comprising a single nucle-
10 otide or two or more nucleotides linked by a phosphate group 
at the 3' position of one nucleotide to the 5' end of another 
nucleotide. The nucleic acid is not limited by length, and thus 
the nucleic acid can include deoxyribonucleic acid (DNA) or 
The term "expression control sequence" refers to a DNA 
sequence that controls and regulates the transcription and/or 
translation of another DNA sequence. Control sequences that 
are suitable for prokaryotes, for example, include a promoter, 15 
optionally an operator sequence, a ribosome binding site, and 
the like. Eukaryotic cells are known to utilize promoters, 
polyadenylation signals, and enhancers. 
ribonucleic acid (RNA). 
"Polypeptide" as used herein refers to any peptide, oli-
gopeptide, polypeptide, gene product, expression product, or 
protein. A polypeptide is comprised of consecutive amino 
acids. The term "polypeptide" encompasses naturally occur-
ring or synthetic molecules. The term "promoter" refers to a regulatory nucleic acid 
sequence, typically located upstream (5') of a gene or protein 20 
coding sequence that, in conjunction with various elements, is 
responsible for regulating the expression of the gene or pro-
tein coding sequence. 
"Inhibit," "inhibiting," and "inhibition" mean to decrease 
an activity, response, condition, disease, or other biological 
parameter. This can include but is not limited to the complete 
ablation of the activity, response, condition, or disease. This 
may also include, for example, a 10% reduction in the activ-The term "operatively linked to" refers to the functional 
relationship of a nucleic acid with another nucleic acid 
sequence. Promoters, enhancers, transcriptional and transla-
tional stop sites, and other signal sequences are examples of 
nucleic acid sequences operatively linked to other sequences. 
For example, operative linkage of DNA to a transcriptional 
control element refers to the physical and functional relation-
ship between the DNA and promoter such that the transcrip-
tion of such DNA is initiated from the promoter by an RNA 
polymerase that specifically recognizes, binds to and tran-
scribes the DNA. 
The term "cell" refers to individual cells, cell lines, primary 
culture, or cultures derived from such cells unless specifically 
indicated. A "culture" refers to a composition having isolated 
cells of the same or a different type. A cell line is a culture of 
25 ity, response, condition, or disease as compared to the native 
or control level. Thus, the reduction can be a 5, 10, 20, 30, 40, 
50, 60, 70, 80, 90, 100%, or any amount of reduction in 
between as compared to native or control levels. With regard 
to eNOS, the reduction of activity refers to ~-actin binding or 
30 NO production. 
"Promote," "promotion," and "promoting" refer to an 
increase in an activity, response, condition, disease, or other 
biological parameter. This can include, but is not limited to, 
the initiation of the activity, response, condition, or disease. 
35 This may also include, for example, a 10% increase in the 
activity, response, condition, or disease as compared to the 
native or control level. Thus, the reduction can be a 5, 10, 20, 
30, 40, 50, 60, 70, 80, 90, 100%, or any amount of increase in 
a particular type of cell that can be reproduced indefinitely, 
thus making the cell line "immortal." A cell culture can be a 40 
population of cells grown on a medium such as agar. A pri-
mary cell culture is a culture from a cell or taken directly from 
between as compared to native or control levels. 
By "treat" or "treatment" is meant the medical manage-
ment of a patient with the intent to cure, ameliorate, stabilize, 
or prevent a disease, pathological condition, or disorder. This 
term includes active treatment, that is, treatment directed 
specifically toward the improvement of a disease, pathologi-
a living organism, which is not immortalized. 
The term "endogenous" with regard to a nucleic acid refers 
to nucleic acids normally present in the host. 
The term "percent (%) sequence identity" is defined as the 
percentage of nucleotides or amino acids in a candidate 
sequence that are identical with the nucleotides or amino 
acids in a reference nucleic acid sequence, after aligning the 
sequences and introducing gaps, if necessary, to achieve the 
maximum percent sequence identity. Alignment for purposes 
of determining percent sequence identity can be achieved in 
various ways that are within the skill in the art, for instance, 
using publicly available computer software such as BLAST, 
BLAST-2,ALIGN,ALIGN-2 or Megalign (DNASTAR) soft-
ware. Appropriate parameters for measuring alignment, 
including any algorithms needed to achieve maximal align-
ment over the full-length of the sequences being compared 
can be determined by known methods. 
For purposes herein, the % sequence identity of a given 
nucleotides or amino acids sequence C to, with, or against a 
given nucleic acid sequence D (which can alternatively be 
phrased as a given sequence C that has or comprises a certain 
% sequence identity to, with, or against a given sequence D) 
is calculated as follows: 
100 times the fraction W /Z, 
45 cal condition, or disorder, and also includes causal treatment, 
that is, treatment directed toward removal of the cause of the 
associated disease, pathological condition, or disorder. In 
addition, this term includes palliative treatment, that is, treat-
ment designed for the relief of symptoms rather than the 
50 curing of the disease, pathological condition, or disorder; 
preventative treatment, that is, treatment directed to minimiz-
ing or partially or completely inhibiting the development of 
the associated disease, pathological condition, or disorder; 
and supportive treatment, that is, treatment employed to 
55 supplement another specific therapy directed toward the 
improvement of the associated disease, pathological condi-
tion, or disorder. 
The term "therapeutically effective" means that the amount 
of the composition used is of sufficient quantity to ameliorate 
60 one or more causes or symptoms of a disease or disorder. Such 
amelioration only requires a reduction or alteration, not nec-
essarily elimination. 
By "pharmaceutically acceptable" is meant a material that 
is not biologically or otherwise undesirable, i.e., the material 
65 may be administered to a subject, along with the disclosed 
polypeptide, without causing any undesirable biological 
effects or interacting in a deleterious marmer with any of the 
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binds the fibrin( ogen) pocket with an affinity at least as strong 
as that ofGHRP (SEQ ID N0:3). 
other components of the pharmaceutical compos1t10n in 
which it is contained. The carrier would naturally be selected 
to minimize any degradation of the active ingredient and to 
minimize any adverse side effects in the subject, as would be 
well known to one of skill in the art. 
II. FIBRIN KNOB PEPTIDES 
The fibrin knob peptide can have the tetrapeptide amino 
acid sequences GPRP (SEQ ID NO:l; A-knob tetrapeptide 
5 mimetic), GPRV (SEQ ID N0:2; native A-knob tetrapeptide ), 
or GHRP (SEQ ID N0:3; native B-knob tetrapeptide). 
Fibrinogen is a symmetrical, rod-shaped molecule having 
two sets of three polypeptides (Aa-, B~-, and y-chains) 
assembled lengthwise and crosslinked at their N-termini via 
multiple disulfide bonds, forming a single central N-terminal 
disulfide knot (NDSK) and two distal globular domains (D 
domains). During the activation of fibrinogen to fibrin mono-
mer, the serine protease thrombin cleaves the N-termini of 
both the Aa- and B~-chains, exposing new cryptic residues 
(i.e. knob-A and knob-B) in the NDSK domain that bind to 
complementary sites (i.e. a- and b-pockets) nearthe two distal 
C-termini of they- andB~-chains within the D domains (FIG. 
The fibrin knob peptide can have the amino acid sequence 
GXRX (SEQ ID NO: 20), where X is any amino acid. The 
fibrin knob peptide can have the amino acid sequence 
10 GX1RX2 (SEQ IDNO: 21), where "X1 " is Pro or His, where 
X2 is Pro or Val. The fibrin knob peptide can include 4, 5, 6, 7, 
8, 9, 10, 11, 12, or more amino an amino acids. 
The peptide can also have additional amino acids that help 
15 stabilize the backbone of the amino acids that binds the fibrin 
1). These non-covalent knob:pocket interactions lead to the 20 
assembly of fibrin protofibrils that make up the fibrin network 
(Lord ST. Curr Opin Hematol 2007, 14(3):236-241; Weisel J 
W. J Thromb Haemost 2007, 5(12):2340-2343). These net-
works are further stabilized by activated transglutaminase 
factor XIII (factor XIIIa) that covalently crosslinks y- and 25 
a-chains of adjacent fibrin monomers within the protofibril 
(Ariens RA, et al. Blood 2002, 100(3):743-754). 
Short synthetic peptides modeled after the fibrin knob 
sequences bind to the C-terminal pockets of fibrin(ogen). 
Specifically, various tetrapeptides have significantly different 30 
affinities for fibrin( ogen) pockets, with GPRP (SEQ ID NO: 1; 
A-knob tetrapeptide mimetic) having the greatest affinity fol-
lowed by GPRV (SEQ ID N0:2; native A-knob tetrapeptide ), 
then GHRP (SEQ ID N0:3; native B-knob tetrapeptide). 
Therefore, an affinity-based scheme stemming from an inher- 35 
ent non-covalent interaction such as the knob:pocket interac-
tion can retain proteins within fibrin matrices without inter-
mediary molecules or enzymes, like factor XIIIa. 
Compositions and methods for conjugating tetrapeptide 
fibrin knob sequences to substances, such as bioactive agents 40 
or inert polymers, are therefore disclosed to endow fibrin-
binding capacities to those substances via knob:pocket inter-
actions. 
The integrin-binding fibronectin 9th and lO'h type III 
repeats (FnIII9 _10) are amenable to recombinant protein pro- 45 
duction, do not bind fibrin(ogen), and have previously been 
shown to induce osteogenic differentiation in mesenchymal 
stem cells (Petrie TA, et al. Biomaterials 2006, 27(31 ):5459-
5470; Martino MM, et al. Biomaterials 2009, 30(6):1089-
1097). Using this protein domain as a model protein, knob- 50 
protein fusions are shown to bind stably to fibrin(ogen) via 
specific knob:pocket interactions. Retention of these fusion 
proteins within fibrin matrices was evaluated through the use 
of ELISA-based protein release assays as well as real-time 
confocal imaging of perfused fibrin matrices. These data 55 
demonstrate the ability to incorporate substances into fibrin 
polymers using fibrin knob peptides. 
A. Fibrin Knobs 
Peptides and fusion proteins containing fibrin knobs are 
disclosed. These peptides preferably have knobs that bind 60 
fibrin( ogen) pockets at the N-terminus of the peptide. There-
fore, peptides and fusion proteins are provided that contain an 
N-terminal peptide sequence, such as a tetrapeptide, that 
binds fibrin(ogen) pockets. 
pocket. The fibrin knob peptide can therefore have the amino 
acid sequence GPRPX (SEQ ID N0:22), GPRVX (SEQ ID 
N0:23), GPRPXX (SEQ ID N0:24), GPRVXX (SEQ ID 
N0:25), GPRPXXX (SEQ ID N0:26), GPRVXXX (SEQ ID 
N0:27), GPRPXXXX (SEQ ID N0:28), or GPRVXXXX 
(SEQ ID N0:29), where Xis any amino acid. The fibrin knob 
peptide can have the amino acid sequence GPRXXX (SEQ ID 
N0:30), where Xis any amino acid. The fibrin knob peptide 
can therefore have the amino acid sequence GPRPAA (SEQ 
ID NO:lO). In preferred embodiments, the fibrin knob pep-
tide has the amino acid sequence GPRPFXX (SEQ ID 
N0:31) or GPRVFXX (SEQ ID N0:32), where Xis any 
amino acid. 
The peptide can also have a C-terminal amino acid, such as 
for example cysteine or lysine, that enables subsequent 
chemical reactions with other agents to produce C-terminal 
conjugates. Therefore, in some embodiments, the C-terminal 
amino acid of the peptide is a cysteine. Therefore, in some 
embodiments, the C-terminal amino acid of the peptide is a 
lysine. For example, the fibrin knob peptide can have the 
amino acid sequence GPRPAAC (SEQ ID N0:4), GPRPF-
PAC (SEQ ID N0:5), GPRPPERC (SEQ ID N0:6), 
GPRVVERC (SEQ ID N0:7), GPRVVAAC (SEQ ID N0:8), 
or GPSPAAC (SEQ ID N0:9). 
The fibrin knob peptide selected can depend on the affinity 
to fibrin that is desired. For example, where a high affinity to 
fibrin is desired, the fibrin knob peptide can have the amino 
acid sequence GPRPFPAC (SEQ ID N0:5). 
1. Variants 
Also disclosed are functional variants of the disclosed 
fibrin knob peptides that can bind fibrin pockets. The term 
"variant" refers to an amino acid or peptide sequence having 
conservative and non-conservative amino acid substitutions, 
insertions or deletions. Substitutions, deletions, insertions or 
any combination thereof may be combined to arrive at a final 
construct. "Functional variants" of the disclosed fibrin knob 
peptides include those that bind fibrin pockets. 
Insertions include amino and/or carboxyl terminal fusions 
as well as intra-sequence insertions of single or multiple 
amino acid residues. Insertions ordinarily will be smaller 
insertions than those of amino or carboxyl terminal fusions, 
for example, on the order of one to four residues. 
Deletions are characterized by the removal of one or more 
amino acid residues from the protein sequence. Thus, the 
polypeptide can have 1, 2, 3, or4 deletions from the disclosed 
reference sequence. These variants ordinarily are prepared by 
site specific mutagenesis of nucleotides in the DNA encoding 
The term "fibrin knob peptide" is used herein to refer to a 
peptide sequence of at least 4 amino acids that binds directly 
to a fibrin(ogen) pocket. Preferably, the fibrin knob peptide 
65 the protein, thereby producing DNA encoding the variant, 
and thereafter expressing the DNA in recombinant cell cul-
ture. 
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Substitutional variants are those in which at least one resi-
due has been removed and a different residue inserted in its 
place. Thus, the polypeptide can also have 1, 2, 3, or 4 sub-
stitutions within the disclosed reference sequence. Tech-
niques for making substitution mutations at predetermined 
sites in DNA having a known sequence are well known, for 
example M13 primer mutagenesis and PCR mutagenesis. 
a. Conservative Substitutions 
In certain embodiments, the protein variant has a conser-
vative amino acid substitution in the disclosed reference 
sequence. The replacement of one amino acid residue with 
another that is biologically and/or chemically similar is 
known to those skilled in the art as a conservative substitution. 
For example, a conservative substitution would be replacing 
one hydrophobic residue for another, or one polar residue for 
another. The substitutions include combinations such as, for 
example, Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gin; Ser, Thr; 
Lys, Arg; and Phe, Tyr. 
In contrast, the substitutions which in general are expected 
to produce the greatest changes in the protein properties will 
be those in which (a) a hydrophilic residue, e.g. seryl or 
threonyl, is substituted for (or by) a hydrophobic residue, e.g. 
leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine 
12 
potency, efficacy, etc.), altered specificity (e.g., a broad-spec-
trum of biological activities), reduced antigenicity, and oth-
ers. 
Thus, also disclosed is a peptidomimetic of the disclosed 
polypeptides that can bind fibrin pockets. The term "peptido-
mimetic" means a mimetic of a peptide which includes some 
alteration of the normal peptide chemistry. Peptidomimetics 
typically enhance some property of the original peptide, such 
as increase stability, increased efficacy, enhanced delivery, 
10 increased halflife, etc. Methods of making peptidomimetics 
based upon a known polypeptide sequence are described, for 
example, in U.S. Pat. Nos. 5,631,280; 5,612,895; and 5,579, 
250. Use of peptidomimetics can involve the incorporation of 
a non-amino acid residue with non-amide linkages at a given 
15 position. One embodiment can be a peptidomimetic wherein 
the compound has a bond, a peptide backbone or an amino 
acid component replaced with a suitable mimic. 
Some non-limiting examples of unnatural amino acids 
which may be suitable amino acid mimics include ~-alanine, 
20 L-a-amino butyric acid, L-y-amino butyric acid, L-a-amino 
isobutyric acid, L-E-amino caproic acid, 7-amino heptanoic 
acid, L-aspartic acid, L-glutamic acid, N-E-Boc-N-a-CBZ-
L-lysine, N-E-Boc-N-a-Fmoc-L-lysine, L-methionine sul-
fone, L-norleucine, L-norvaline, N-a-Boc-N-1\CBZ-L-orni-
25 thine, N-1\-Boc-N-a-CBZ-L-ornithine, Boc-p-nitro-L-
phenylalanine, Boc-hydroxyproline, and Boc-L-thioproline. 
or praline is substituted for (or by) any other residue; (c) a 
residue having an electropositive side chain, e.g., lysyl, argi-
nyl, or histidyl, is substituted for (or by) an electronegative 
residue, e.g., glutamyl or aspartyl; or (d) a residue having a 30 
bulky side chain, e.g., phenylalanine, is substituted for (or by) 
one not having a side chain, e.g., glycine, in this case, ( e) by 
increasing the number of sites for sulfation and/or glycosy-
lation. 
There are also numerous D amino acids or amino acids 
which have a different functional substituent than natural 
amino acids. The opposite stereo isomers of naturally occur-
ring peptides are disclosed, as well as the stereo isomers of 
peptide analogs. These amino acids can readily be incorpo-
rated into polypeptide chains by charging tRNA molecules 
with the amino acid of choice and engineering genetic con-
structs that utilize, for example, amber codons, to insert the 
b. Percent Identity 
It is understood that one way to define the variants and 
derivatives of the disclosed polypeptides disclosed herein is 
through defining the variants and derivatives in terms of 
homology/identity to specific known sequences. Thus, dis-
closed are variants of these and other disclosed proteins. For 
example, disclosed are polypeptides having at least, 5, 6, or 7 
of the 8 amino acids in a polypeptide sequence disclosed 
herein. Also disclosed are polypeptides having at least 65%, 
70%, 71 %, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 
80%, 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 
90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% 
identity to a polypeptide sequence disclosed herein. 
35 analog amino acid into a peptide chain in a site specific way 
(Thorson et al., Methods in Malec. Biol. 77:43-73 (1991), 
Zoller, Current Opinion in Biotechnology, 3:348-354 (1992); 
Ibba, Biotechnology & Genetic Engineering Reviews 
13:197-216 (1995), Cahill et al., TIBS, 14(10):400-403 
40 (1989); Benner, TIB Tech, 12:158-163 (1994); Ibba and Hen-
necke, Bio/technology, 12:678-682 (1994) all of which are 
herein incorporated by reference at least for material related 
to amino acid analogs). D-amino acids can be used to gener-
ate more stable peptides, because D amino acids are not 
45 recognized by peptidases and such. Systematic substitution 
of one or more amino acids of a consensus sequence with a 
D-amino acid of the same type (e.g., D-lysine in place of 
L-lysine) can be used to generate more stable peptides. 
50 d. Modified Amino Acid Linkages 
It is understood that the description of conservative muta-
tions and sequence identity can be combined together in any 
combination, such as embodiments that have at least 65%, 
70%, 71 %, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 
80%, 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 55 
90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% 
sequence identity to a particular sequence wherein the vari-
Molecules can be produced that resemble peptides, but 
which are not connected via a natural peptide linkage. For 
example, linkages for amino acids or amino acid analogs can 
include CH2NH-, --CH2S-, -CH2-CH2-, 
--CH=CH- ( cis and trans), --COCH2-, CH(OH)CH2-, 
and--CHH2SO- (these and others can be found in Spatola, 
A. F. in Chemistry and Biochemistry of Amino Acids, Pep-
tides, and Proteins, B. Weinstein, eds., Marcel Dekker, New 
ants are conservative mutations. 
c. Analogs and Mimetics 
It is understood that there are numerous amino acid and 
peptide analogs which can be incorporated into the disclosed 
compositions. Amino acid analogs and analogs and peptide 
analogs often have enhanced or desirable properties, such as, 
more economical production, greater chemical stability, 
enhanced pharmacological properties (half-life, absorption, 
60 York, p. 267 (1983); Spatola, A. F., Vega Data (March 1983), 
Vol. 1, Issue 3, Peptide Backbone Modifications; Morley, 
Trends Phann Sci (1980) pp. 463-468; Hudson, D. et al., Int 
J Pept Prat Res 14:177-185 (1979) (-CH2NH-, 
CH2CH2-); Spatola et al. Life Sci 38:1243-1249 (1986) 
65 (-CH H2-S); Hann J. Chem. Soc Perkin Trans. I 307-314 
(1982) (--CH--CH-, cis and trans); Almquist et al. J. Med. 
Chem. 23:1392-1398 (1980) (-COCH2-); Jennings-White 
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eta!. TetrahedronLett23:2533 (1982) (-COCH2-); Szelke 
et al. European Appln, EP 45665 CA (1982): 97:39405 
(1982) (-CH(OH)CH2-); Holladay et al. Tetrahedron. Lett 
24:4401-4404 (1983) (-C(OH)CH2-); and Hruby Life Sci 
31:189-199 (1982) (--CH2-S-); each of which is incorpo- 5 
rated herein by reference. A particularly preferred non-pep-
tide linkage is --CH2NH-. It is understood that peptide 
analogs can have more than one atom between the bond 
atoms, such as b-alanine, g-aminobutyric acid, and the like. 
Cysteine residues can also be used to cyclize or attach two 10 
or more peptides together. This can be beneficial to constrain 
peptides into particular conformations. (Rizo and Gierasch 
Ann. Rev. Biochem. 61:387 (1992), incorporated herein by 
reference). 
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epitope tag that can specifically interact with a molecule that 
can be detected, such as by producing a colored substrate or 
fluorescence. 
1. Bioactive Proteins or Domains 
Fibrin knob peptides can be conjugated to proteins or bio-
active peptide domains. For example, the protein/peptide can 
be a therapeutic agent. The disclosed design for a fibrin-based 
therapeutic delivery system simplifies the mode of therapeu-
tic incorporation by coupling, at the genetic level, the ele-
ments of fibrin knob that display fibrin-binding capacity and 
drive polymer formation and a deliverable protein/peptide 
species. The advantage of this design is that the deliverable 
B. Conjugates 
A conjugate of a substance, such as a peptide, protein, or 
polymer, to the C-terminus of a knob peptide is also dis-
closed. Where the substance is a protein, the conjugate is 
preferably a fusion protein. Therefore, a fusion protein is 
disclosed that has a knob peptide at the N-terminus. 
15 protein species can be incorporated prior to the initiation of 
polymer formation and without additional steps or reagents. 
The capacity to bind the polymerization pocket(s) of fibrino-
gen also allows for the potential to develop technologies that 
modify the characteristics of the polymer if added in appro-
For example, a fusion protein is disclosed having the for-
mula: 
20 priate stoichiometries. 
a. Growth Factors 
Fibrin knob peptides can be conjugated to a growth factor. 
where "Fkp" is a fibrin knob peptide disclosed herein and "P" 25 For example, the growth factor can be a vascular endothelial 
is a peptide or protein, such as a bioactive protein or an inert growth factor, platelet-derived growth factor, fibroblast 
Fkp-P, 
carrier. The Fkp can be GXXX (SEQ ID N0:20), where "X" growth factor, transforming growth factor-beta, insulin-like 
is any amino acid. The Fkp can be GX1 RX2 (SEQ ID N0:21 ), growth factor, parathyroid hormone, angiopoietin, throm-
where "X1" is Pro or His, where X2 is Pro or Val. Therefore, bopoietin, connective tissue growth factor, nerve growth fac-
the Fkp can be GPRP (SEQ ID NO: 1 ), GPRV (SEQ ID 30 tor, neurotrophin, or epidermal growth factor. 
N0:2), orGHRP (SEQ ID N0:3), wherein "P"is a peptide or Some of the growth factors, such as the fibroblast growth 
protein. factors, are monomeric, and these can be incorporated 
The dashes in the formula can represent either a direct link directly and without complexity as domains in a fusion pro-
between the N-terminus of the bioactivepeptide and the fibrin tein with fibrin knob peptides. Other growth factors, such as 
knob, additional amino acids in the knob peptide, or a linker 35 vascular endothelial growth factor, are dimeric. In such cases, 
joining the protein and peptide. For example, the Fkp can be it may be necessary to incorporate one monomer unit as a 
GPRPAAC (SEQ ID N0:4), GPRPFPAC (SEQ ID N0:5), domain in the fusion protein, and then co-express an addi-
GPRPPERC (SEQ ID NO: 6), GPRVVERC (SEQ ID N0:7), tional monomer of the growth factor as a soluble protein o that 
GPRVVAAC (SEQ ID N0:8), GPSPAAC (SEQ ID N0:9), or this monomer will dimerize with the monomer in the fusion 
GPRPAA (SEQ ID NO: 10). 40 protein. This could thus involve expressing both the monomer 
As noted above, a fusion protein was generated for proof of and the monomer-containing fusion protein, either simulta-
principle using the integrin-binding fibronectin 9th and lO'h neously or sequentially. 
type III repeats (FnIII9_10). This fusion protein is designated In some embodiments, the fusion protein contains knob 
Gxxx-FnIII9_10 (SEQ ID N0:20), which included GPRP- peptides and full length growth factors. In other embodi-
FnIII9_10 (SEQ ID NO:l), GPRV-FnIII9_10 (SEQ ID N0:2), 45 ments, the fusion protein contains knob peptides and a bio-
and GHRP-FnIII9_10 (SEQ ID N0:3). active fragment of the growth factor, such as the receptor-
The formula also includes additional moieties at the C-ter- binding domain of the growth factor. 
minus of the fusion protein. For example, a C-terminal cys-
teine can be added to the fusion protein. For example, a fusion 
protein containing FnIII9_10 and a C-terminal cysteine was 50 
produced and is designated Gxxx-FnIII9_10-C (SEQ ID 
N0:20), which includes GPRP-FnIII9_10-C (SEQ ID N0:2). 
This C-terminal cysteine can be used to conjugate other 
moieties on the C-terminus. For example, the fusion protein 
can be conjugated via the sulfhydryl group of the C-terminal 55 
cysteine to maleimide-functionalized biotin. For example, a 
fusion protein containing FnIII9_10 and a C-terminal biotin 
was produced and is designated Gxxx-FnIII9_10-biotin (SEQ 
ID N0:20), which includes GPRP-FnIII9_10-biotin (SEQ ID 
N0:2). 60 
Similarly, the fusion protein can be labeled with carboxylic 
acid terminated label. For example, a fusion protein contain-
ing FnIII9_10 and a C-terminal Alexa Fluor-555 or Alexa 
Fluor-633 was produced. A label can be used, for example, to 
detect fibrin in a subject. As used herein, a label can include a 65 
fluorescent dye, a radioactive isotope, a member of a binding 
pair, such as biotin/streptavidin, a metal (e.g., gold), or an 
b. Cytokines and Chemokines 
Fibrin knob peptides can be conjugated to cytokines or 
chemokines. Just as growth factors are powerful morphogens, 
chemokines and cytokines are powerful cellular regulators 
and morphogens. These include the interleukins, platelet acti-
vating factors, the CCR molecules, the CXC molecules, and 
many other families of proteins. Incorporation of these mol-
ecules can be carried out as for growth factors. 
c. Adhesion Domains 
Fibrin knob peptides can be conjugated to adhesion 
domains. Many extracellular matrix molecules and matricel-
lular signal through their adhesion domains, including col-
lagens, laminin, fibronectin, vitronectin, thrombospondins, 
Ll, SPARC family members, elastin, ostopontin, the CCN 
family, ICAMs, CAMs, dystrophin, dystroglyan, proteogly-
cans, and so forth. The domains of these proteins that bind to 
US 8,513,380 B2 
15 
the cell adhesion receptors on cells can often be localized to 
smaller domains of these proteins. 
16 
ally, and oligomers and polymers of lyine, argine, and histi-
dine also bind DNA. Such domains can be conjugated to 
fibrin knob peptides, for the purpose of binding do DNA in 
gene delivery, antisense oligonucleotide delivery, si-RNA 
delivery, and so forth. 
h. Polysaccharide-Binding Domains 
Fibrin knob peptides n polysaccharide-binding domains, 
e.g. those having affinity for heparin, heparan sulfate, chon-
drointin sulfate, dermatan sulfate, and so forth. These 
domains may be useful to immobilize polysaccharides within 
fibrin matrices, either because of the active character of the 
polysaccharide or due to its ability to bind to other proteins. 
i. Virus-Binding Domains 
An illustrative example is fibronectin, in which the 9th and 
10th type-III repeat domains contain two cell-binding 
domains that operate alone or in synchrony, namely an RDG 
site and a PHSRN (SEQ ID N0:37) site. Therefore, in this 
case, fibrin knobs can be conjugated to a short peptide com-
prising the sequence RGD, a short peptide comprising the 
sequence PHSRN (SEQ ID N0:37), the 9th type-III domain 
itself, the 10th type-III domain itself, or both the 9th and the 10 
10th type-III domains. Most powerfully, whole protein 
domains can be used, allowing the fullness of their evolution-
arily-determined structure to be incorporated into the fibrino-
gen variant. These adhesion domains can be useful for incor-
porating migration-inducing, angiogenic, and more generally 15 
morphogenetic character into fibrin gels formed including the 
adhesion domain-containing fibrinogen mutant. Fibrin knob peptides can be conjugated to virus-binding 
domains. Some proteins bind to viral coat proteins, e.g. the 
coxsackie-adenoviral receptor. Incorporation of such virus-
20 binding domains can be accomplished for better retention and 
delivery of viral vectors in gene delivery. 
d. Antiadhesion Domains 
Fibrin knob peptides can be conjugated to anti-adhesion 
domains. Some proteins function as negative regulators of 
cell adhesion, repelling rather than inducing cell adhesions. 
These molecules include domains of thrombospondin, such 
as the SPAC domain. Incorporation of these molecules can be 25 
carried out as for the adhesion proteins. They can be useful in 
preventing scar formation, in preventing cellular migration 
and infiltration. 
j. Cytotoxic Domains 
e. Immunomodulatory Domains 
Fibrin knob peptides can be conjugated to cytotoxic 
domains. Some proteins bind to cell-surface receptors and 
induce cell death via apoptosis. These proteins include the 
FAS ligand. Incorporation of such domains can be accom-
plished for prevention of scar formation, cell infiltration and 
cell migration, and can be useful in the local treatment of 
30 tumors. 
Fibrin knob peptides can be conjugated to immunomodu-
latory domains. Some proteins function as immunostimula-
tory and immunomodulatory molecules. One example is 
flagellin, a domain of which is known to bind to members of 35 
the toll-like receptor family and activate maturation of den-
dritic cells, leading to more effective antigen presentation and 
maturation of immune responses. In this case, either the 
whole protein flagellin or domains of flagellin can be conju-
gated to fibrin knob peptides. Other proteins of interest 40 
include bacterial coat proteins, mannose receptor ligands, and 
viral coat proteins. 
f. Protein-Binding Domains 
45 
Fibrin knob peptides can be conjugated to protein-binding 
domains. Many proteins have evolved binding domains for 
other proteins. For example, members of the transforming 
growth factor beta family bind to extracellular matrix proteins 
such as members of the collagen family. In this case, such 50 
domains of collagen can be conjugated to fibrin knob pep-
tides. Alternatively, protein-binding domains could be iden-
tified by computational methods or by combinatorial methods 
conjugation to peptide knob peptides. As a specific example 
k. Enzymatically Active Domains 
Fibrin knob peptides can be conjugated to enzymatically 
active domains. Some proteins have enzymatic activity, such 
as proteases and transglutaminases. These proteins can be 
incorporated to provide a long-term chemically reactive char-
acter to the resulting fibrin gel, including the ability to locally 
convert pro-drugs to active drugs within the fibrin matrix 
containing such an enzyme as an X domain in a fibrinogen 
fusion protein. Proteases incorporated as an X domain may 
influence fibrin degradation rate, and transglutaminases may 
incorporate other exogenous proteins within the fibrin net-
work or also influence degradation rate. 
I. Protease Inhibitors 
Fibrin knob peptides can be conjugated to protease inhibi-
tors. Some proteins inhibit proteases, and these can be incor-
porated to influence degradation rate of the resulting fibrin 
network or of other matrix proteins co-incorporated within 
the fibrin matrix. For example, the fibrin knob peptides can be 
conjugated to aprotinin. 
m. Serum Proteins 
Fibrin knob peptides can be conjugated to serum proteins. 
of protein-binding domains, proteins that bind to the extra- 55 
cellular matrix molecules are of particular interest in regen-
erative medicine, including fibronectin, which binds collagen 
and thrombospondin; and nidogen, which binds elastins and 
laminins. 
Some proteins have little enzymatic, inflammatory, or immu-
nogenic activity and may be used to enhance the pharmaco-
60 kinetics such that the fusion protein displays extended circu-
lation/residence times. These are also useful as inert carriers 
as discussed below. 
g. Nucleic Acid-Binding Domain 
Fibrin knob peptides can be conjugated to a nucleic acid-
binding domain. Many proteins contain DNA-binding and 
RNA-binding domains. Such proteins include transcription 65 
factors and histone proteins. Moreover, DNA-binding 
domains can be identified computationally or combinatori-
3. Environmentally-Responsive Elements 
Rapid polymerization is ideal in the native system (i.e. in 
the blood stream) where the rate-limiting step in this process 
US 8,513,380 B2 
17 18 
is the generation of active thrombin. However, in the exog-
enous system used by health care professionals, which uti-
lizes purified fibrinogen and thrombin, rapid polymerization 
complicates the delivery of the polymer in situ. Specialized 
syringe delivery systems have been developed to minimize 
this problem, yet without adequate training and practice this 
syringe system is rendered less effective. In addition to prob-
lems arising from polymerization in the delivery system, the 
rapid polymerization of fibrin leads to problems in reproduc-
ibility in the polymer application and an inadequate working 10 
time. This lack of reproducibility significantly affects the 
safety and efficacy of the system and the short working-time 
limits the number of possible applications the polymer can be 
used for as well as the ease of use. 
a. Elastin-Like Polypeptides 
Therefore, the fibrin knob peptides can be conjugated to 
elastin-like polypeptides (ELPs) to produce peptides with 
temperature sensitive binding to fibrin(ogen). ELPs are 
thermo-responsive polymers containing repeats of the pen-
tapeptide sequence VPGXG (SEQ ID N0:38), where Xis any 
amino acid with the exception of pro line. A Pro substitution at 
the fourth position destroys the inverse phase transition. This 
sequence is derived from the characteristic repeat motif found 
in exon 20 of native mammalian elastic protein, elastin. The 
soluble precursor to elastin, the 70 kDa tropoelastin, has been 
shown to undergo a reversible phase separation where the 
protein self-aggregates under increasing temperature. It has 
However, conjugating fibrin knob peptides to environmen-
tally-responsive elements can be used to decouple fibrin poly-
merization from thrombin activation and instead couple it to 
more application specific stimuli. This can greatly improve 
the utility and reproducibility of the system. 
The environmentally-responsive element conjugated to 
fibrin knobs can be a phase transition polymer. Phase transi-
tion polymers register a distinctive change in properties upon 
a modest change in environmental conditions, such as tem-
perature or pH. In the context of biomedical applications that 
deal with aqueous systems, the phase transition commonly 
refers to a volume-phase transition due to changes in the 
salvation state, with the polymer quickly transitioning from a 
soluble/expanded state to an insoluble/collapsed state 
depending on the environmental condition. This change in 
salvation state reflects competing inter- and intra-molecular 
hydrogen bonding properties of the polymer with a solubili-
zation by water and is usually reversible. Additionally, the 
point of transition can be fine-tuned to the researchers' needs 
by directly altering the polymer composition, or changing 
auxiliary factors such as salt concentration, surfactants, or 
co-solvents. 
Preferably, the phase transition polymer is a thermo-re-
sponsive polymer. Thermo-responsive polymers that become 
insoluble upon heating have a lower critical solution tempera-
ture (LCST), whereas polymers that become soluble upon 
heating have an upper critical solution temperature (UCST). 
Polymers that exhibit UCST behavior in the biomedical con-
text are rare. Typical LCST polymers include poly-N-isopro-
pylacrylamide (PNIPAM, LCST -32° C.), poly-methylvi-
nylether (PMVE, LCST -40° C.) and poly-N-
vinylcaprolactam (PVCa, LCST -30° C.). In particular, the 
biocompatibility and position of the LCST for PNIPAM has 
made it a well-studied polymer for use in drug delivery and 
tissue engineering. Several groups have studied the loading 
and release kinetics of peptides from PNIPAM at different 
temperatures, indicating the feasibility of the system for use 
as an on-off switch for the in vivo delivery of peptides. 
15 been suggested that this phenomenon (known as coacerva-
tion) is necessary, and perhaps sufficient, for the in vivo 
assembly oftropoelastin into the crosslinked polymeric net-
work that makes up the insoluble extracellular matrix called 
elastin. Coacervation may assists in the aligriment of lysine 
20 crosslinking sites within the molecule. Evidence to this effect 
is that short elastin polypeptides containing hydrophobic 
domain-generating exons 20 and 24 with interspersed 
crosslinking domain-generating exons 21 and 23 not only 
undergo coacervation but are capable of forming insoluble 
25 crosslinked elastin-like matrix. 
The coacervation ofELPs, which can be determined spec-
tra-photometrically by monitoring solution turbidity at 350 
nm, occurs typically over a 2° C. range, with the transition 
temperature (T ,) defined as the temperature at 50% maximal 
30 turbidity. The T,is a function of the sequence, the identity and 
mole fraction of guest residues at the fourth position of the 
ELP and the chain length. In general, increasing hydropho-
bicity of the fourth amino acid in SEQ ID N0:38 and chain 
length both reduce T,. The model ELP places Val at the fourth 
35 position (VPGVG, SEQ ID N0:39). ELPs with guest resi-
dues having simple aliphatic side chains produce a consistent 
and acute thermal response under most experimental condi-
tions. Complex ELPs use functionalized guest residues that 
can act as cross-linkers and also affect the transitioning prop-
40 erties of the polymer. For example, ELPs with ionizable guest 
residues can display different T, depending on whether they 
are present in the protonated or deprotonated state. In a like 
manner, the genetic fusion of an ELP to a protein alters the T, 
presumably by altering the hydrophobicity of the complex. 
45 Despite the altered T ,, one of the most promising uses ofELPs 
is to facilitate the purification schemes of recombinant pro-
teins. In addition to utilization for protein purification, ELPs 
have been designed and tested as macromolecular carriers for 
thermal targeting of therapeutics to various tissues, most 
50 notably solid tumors, but also intra-articular spaces among 
others. ELPs have also been successfully used as temperature 
sensitive switches for the binding and release of molecules in 
biosensors. This technology is made possible due to the 
physical force that can be generated by ELPs as a result of the 
Certain polypeptides also exhibit LCST behavior, includ-
ing elastin-like polypeptides (ELPs). However, unlike LCST 
polymers, ELPs have the additional property of being able to 
self-assemble into ordered arrays of ~-spirals above their 
transition temperature. This phenomenon is separately 
referred to as inverse temperature transition. The use of 
recombinant polypeptides is particularly advantageous for 
several reasons. First, a monodispersed product is produced, 60 
allowing the accurate and reproducible characterization of its 
phase transition properties. Second, varying the amino acid 
sequence of the recombinant plasmid, through recursive 
directional ligation can easily generate polymers of the 
desired thermal characteristics. Third, ELPs are well taler- 65 
ated by the body and their degradation products are naturally 
occurring amino acids. 
55 phase transition. 
4. Inert Carriers 
Fibrin knob peptides can be conjugated to inert carriers to 
block the self-binding pockets of fibrinogen (and fibrin 
monomers). Through saturation with this conjugate, one can 
effectively "cap" the growing polymer, which can decrease 
the fibrotic response. A conjugate of a fibrin knob peptide and 
an inert carrier can bind to fibrinogen and fibrin monomers 
and prevent self-binding to the polymerization pocket of 
fibrinogen. This interaction can inhibit fibrin formation in a 
dose dependent fashion. Consequently, this conjugate can be 
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used to diminish the formation of fibrin following injuries, 
such as wounds, surgical abdominal cavity abrasions (which 
lead to postsurgical adhesions), or pulmonary damage, and 
thus limit the extent of scar formation and pulmonary fibrosis. 
20 
example, the fibrin knob peptides can be conjugated to a 
fluorophore. Fluorophores are compounds or molecules that 
luminesce. Typically fluorophores absorb electromagnetic 
The conjugate is predicted to function by two mechanisms, 5 
first by blocking fibrin formation and second by increasing 
the sensitivity of the polymer that may form to enzymatic 
degradation through its incorporation. 
energy at one wavelength and emit electromagnetic energy at 
a second wavelength. 
Representative fluorophores include, but are not limited to, 
1,5 IAEDANS; 1,8-ANS; 4-Methylumbelliferone; 5-car-
boxy-2, 7-dichlorofluorescein; 5-Carboxyfluorescein 
( 5-FAM); 5-Carboxynapthofluorescein; 5-Carboxytetram-
a. Human Serum Albumin 
The inert carrier can be human serum albumin (HSA). Due 
to the prolonged circulation half-life and low immunogenic-
ity, HSA can be used for clinical molecular delivery. HSA has 
been used as the protein component in several protein poly-
mer systems. The low bioreactivity to the protein makes it an 
ideal protein for in-vivo applications. Although polymor-
phisms in the DNA do exist, the primary sequence is known. 
rHSA has been used to produce genetic fusions to protein 
therapeutics for increasing their circulation times while lim-
iting their immunogenicity. 
b. Polymers 
The inert carrier can be a polymer, such as polyethylene 
glycol. PEGylation, or the covalent attachment of PEG to 
molecules of interest, is an enabling technology that is rou-
tinely used to improve the physiochemical characteristics of 
therapeutic drugs and proteins. PEGylation reduces the 
immunogenicity of proteins while preserving their enzymatic 
activity. PEGylation reduces the immunogenicity of mol-
ecules by reducing their accessibility to antibodies and pro-
teolytic enzymes through steric hindrance imparted by the 
mobile polymer chains. The hydrophilic PEG chains also 
impart solubility and increase the hydrodynamic radius of the 
parent molecule, thus reducing kidney clearance and increas-
ing the blood circulation time of small proteins or peptides. 
High quality PEGs of various conjugation chemistries and 
structures are now available commercially (Laysan Bio, 
Arab, Ala.; JenKem Technology USA, Allen, Tex.; NOF Cor-
poration, Tokyo, Japan). Conjugation via the sulfhydryl 
group of cysteine is one of the most specific methods of in 
vitro protein modification due to the lower abundance of 
cysteine residues as compared to amine-containing lysine 
residues. Use of this strategy in PEGy la ti on has been gaining 
popularity as genetic engineering and recombinant protein 
production allows for the introduction of deliberately placed 
cysteine residues for site-directed conjugation. [58-60] This 
is particularly useful when amino groups are involved in 
protein function since amine-mediated conjugation chemis-
tries might inadvertently target the active site of the protein, 
resulting in an inactive conjugate. In particular, the sulfhy-
dryl-maleimide reaction can be carried out efficiently under 
mild conditions so as to preserve protein/peptide function. 
Therefore, Fibrin knobs peptides containing cysteine resi-
dues at the C-terminus can be conjugated to polyethylene 
glycol by a sulfhydryl-maleimide reaction. PEGylation in 
this context provides a convenient and reproducible means of 
generating fibrin-binding PEGs with different peptide con-
figurations (e.g. mono-, bi-, multi-valent) on a single inert 
polymer backbone enabling the regulation of fibrin formation 
and polymer structure. 
5. Other Conjugates? 
Fibrin knob peptides can be conjugated to imaging conju-
gates that allow one to detect fibrin polymers in a subject. For 
10 ethylrhodamine (5-TAMRA); 5-Hydroxy Tryptamine 
(5-HAT); 5-ROX (carboxy-X-rhodamine); 6-Carbox-
yrhodamine 6G; 6-CR 6G; 6-JOE; 7-Amino-4-methylcou-
marin; 7-Aminoactinomycin D (7-AAD); 7-Hydroxy-4-I 
methylcoumarin; 9-Amino-6-chloro-2-methoxyacridine 
15 (ACMA); ABQ; Acid Fuchsin; Acridine Orange; Acridine 
Red; Acridine Yellow; Acriflavin; Acriflavin Feulgen SITSA; 
Aequorin (Photoprotein); AFPs-AutoF!uorescent Pro-
tein-(Quantum Biotechnologies) see sgGFP, sgBFP; Alexa 
Fluor 350™; Alexa Fluor 430™; Alexa Fluor 488™; Alexa 
20 Fluor 532™; Alexa Fluor 546™; Alexa Fluor 568™; Alexa 
Fluor 594™; Alexa Fluor 633™; Alexa Fluor 647™; Alexa 
Fluor 660™; Alexa Fluor 680™; Alizarin Complexon; 
Alizarin Red; Allophycocyanin (APC); AMC, AMCA-S; 
Aminomethylcoumarin (AMCA); AMCA-X; Aminoactino-
25 mycin D; Aminocoumarin; Anilin Blue; Anthrocyl stearate; 
APC-Cy7; APTRA-BTC; APTS; Astrazon Brilliant Red 4G; 
Astrazon Orange R; Astrazon Red 6B; Astrazon Yellow 7 
GLL; Atabrine; ATTO-TAG™ CBQCA; ATTO-TAG™ FQ; 
Auramine; Aurophosphine G; Aurophosphine; BAO 9 
30 (Bisaminophenyloxadiazole); BCECF (high pH); BCECF 
(low pH); Berberine Sulphate; Beta Lactamase; BFP blue 
shifted GFP(Y66H); Blue Fluorescent Protein; BFP/GFP 
FRET; Bimane; Bisbenzemide; Bisbenzimide (HO-
ECHST®); bis-BTC; Blancophor FFG; Blancophor SV; 
35 BOB0™-1; BOB0™-3; Bodipy492/515; Bodipy493/503; 
Bodipy500/510; Bodipy; 505/515; Bodipy 530/550; Bodipy 
542/563; Bodipy 558/568; Bodipy 564/570; Bodipy 576/589; 
Bodipy 581/591; Bodipy 630/650-X; Bodipy 650/665-X; 
Bodipy 665/676; Bodipy Fl; Bodipy FL ATP; Bodipy Fl-
40 Ceramide; Bodipy R6G SE; Bodipy TMR; Bodipy TMR-X 
conjugate; BodipyTMR-X, SE; BodipyTR; BodipyTRATP; 
Bodipy TR-X SE; BO-PR0™-1; BO-PR0™-3; Brilliant 
SulphoflavinFF; BTC; BTC-5N; Calcein; CalceinB!ue; Cal-
cium Crimson-; Calcium Green; Calcium Green-1 Ca2+ Dye; 
45 Calcium Green-2 Ca2+; Calcium Green-SN Ca2 +; Calcium 
Green-C18 Ca2+; Calcium Orange; Calcofluor White; Car-
boxy-X-rhodamine (5-ROX); Cascade Blue™; Cascade Yel-
low; Catecholamine; CCF2 GENEBLAZER®); CFDA; CFP 
(Cyan Fluorescent Protein); CFP/YFP FRET; Chlorophyll; 
50 Chromomycin A; Chromomycin A; CL-NERF; CMFDA; 
Coelenterazine; Coelenterazine cp; Coelenterazine f; 
Coelenterazine fcp; Coelenterazine h; Coelenterazine hep; 
Coelenterazine ip; Coelenterazine n; Coelenterazine O; Cou-
marin Phalloidin; C-phycocyanine; CPM I Methylcoumarin; 
55 CTC; CTC Formazan; Cy2™; Cy3.1 8; Cy3.5™; Cy3™; 
Cy5.1 8; Cy5.5™; Cy5™; Cy7™; Cyan GFP; cyclic AMP 
Fluorosensor (FiCRhR); Dabcyl; Dansyl; Dansyl Amine; 
Dansyl Cadaverine; Dansyl Chloride; Dansyl DHPE; Dansyl 
fluoride; DAPI; Dapoxyl; Dapoxyl 2; Dapoxyl 3'DCFDA; 
60 DCFH (Dichlorodihydrofluorescein Diacetate); DDAO; 
DHR (Dihydrorhodamine 123); Di-4-ANEPPS; Di-8-
ANEPPS (non-ratio); DiA (4-Di 16-ASP); Dichlorodihy-
drofluorescein Diacetate (DCFH); DiD-Lipophilic Tracer; 
DiD (Di!C18(5)); DIDS; Dihydrorhodamine 123 (DHR); Di! 
65 (Di!C18(3)); I Dinitrophenol; DiO (DiOC18(3)); DiR; DiR 
(Di!C18(7)); DM-NERF (high pH); DNP; Dopamine; 
DsRed; DTAF; DY-630-NHS; DY-635-NHS; EBFP; ECFP; 
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EGFP; ELF 97; Eosin; Erythrosin; Erythrosin ITC; Ethidium 
Bromide; Ethidium homodimer-1 (EthD-1 ); Euchrysin; 
EukoLight; Europium (111) chloride; EYFP; Fast Blue; 
FDA; Feulgen (Pararosaniline); FIF (Formaldehyde Induced 
Fluorescence); FITC; Flazo Orange; Fluo-3; Fluo-4; Fluores- 5 
cein (FITC); Fluorescein Diacetate; Fluoro-Emerald; Fluoro-
Gold (Hydroxystilbamidine); Fluor-Ruby; Fluor X; FM 
1-43™; FM 4-46; Pura Red™ (high pH); Pura Red™/Fluo-3; 
Fura-2; Fura-2/BCECF; Genacryl Brilliant Red B; Genacryl 
Brilliant Yellow lOGF; Genacryl Pink 3G; Genacryl Yellow 10 
5GF; GENEBLAZER®; (CCF2); GFP (S65T); GFP red 
shifted (rsGFP); GFP wild type' non-UV excitation (wtGFP); 
GFP wild type, UV excitation (wtGFP); GFPuv; Gloxalic 
Acid; Granular blue; Haematoporphyrin; HOECHST® 
33258; HOECHST® 33342; HOECHST® 34580; HPTS; 15 
Hydroxycoumarin; Hydroxystilbamidine (FluoroGold); 
Hydroxytryptamine; Indo-1, high calcium; Indo-1 low cal-
cium; Indodicarbocyanine (DiD); Indotricarbocyanine 
(DiR); Intrawhite Cf; JC-1; JO J0-1; JO-PR0-1; LaserPro; 
Laurodan; LDS 751 (DNA); LDS 751 (RNA); Leucophor 20 
PAF; Leucophor SF; Leucophor WS; Lissamine Rhodamine; 
Lissamine Rhodamine B; Calcein/Ethidium homodimer; 
LOL0-1; LO-PR0-1; Lucifer Yellow; Lyso Tracker Blue; 
Lyso Tracker Blue-White; Lyso Tracker Green; Lyso Tracker 
Red; Lyso Tracker Yellow; LysoSensor Blue; LysoSensor 25 
Green; LysoSensor Yellow/Blue; Mag Green; Magdaia Red 
(PhloxinB); Mag-Pura Red; Mag-Fura-2; Mag-Fura-5; Mag-
Indo-1; Magnesium Green; Magnesium Orange; Malachite 
Green; Marina Blue; I Maxilon Brilliant Flavin 10 GFF; 
Maxilon Brilliant Flavin 8 GFF; Merocyanin; Methoxycou- 30 
marin; Mitotracker Green FM; Mitotracker Orange; 
Mitotracker Red; Mitramycin; Monobromobimane; Mono-
bromobimane (mBBr-GSH); Monochlorobimane; MPS 
(Methyl Green Pyronine Stilbene ); NBD; NBD Amine; Nile 
Red; Nitrobenzoxedidole; Noradrenaline; Nuclear Fast Red; 35 
i Nuclear Yellow; Nylosan Brilliant lavin E8G; Oregon 
Green™; Oregon Green™ 488; Oregon Green™ 500; 
Oregon Green™ 514; Pacific Blue; Pararosaniline (Feulgen); 
PBFI; PE-Cy5; PE-Cy7; PerCP; PerCP-Cy5.5; PE-TexasRed 
(Red 613); PhloxinB (Magdaia Red); PhorwiteAR; Phorwite 40 
BKL; Phorwite Rev; Phorwite RPA; Phosphine 3R; Photo-
Resist; Phycoerythrin B [PE]; Phycoerythrin R [PE]; PKH26 
(Sigma); PKH67; PMIA; Pontochrome Blue Black; POP0-1; 
POP0-3; PO-PR0-1; PO-I PR0-3; Primuline; Procion Yel-
low; Propidium lodid (PI); PyMPO; Pyrene; Pyronine; Pyro- 45 
nine B; Pyrozal Brilliant Flavin 7GF; QSY 7; Quinacrine 
Mustard; Resorufin; RH 414; Rhod-2; Rhodamine; 
Rhodamine 110; Rhodamine 123; Rhodamine 5 GLD; 
Rhodamine 6G; Rhodamine B; Rhodamine B 200; 
Rhodamine B extra; Rhodamine BB; Rhodamine BG; 50 
Rhodamine Green; Rhodamine Phallicidine; Rhodamine: 
Phalloidine; Rhodamine Red; Rhodamine WT; Rose Bengal; 
R-phycocyanine; R-phycoerythrin (PE); rsGFP; S65A; 
S65C; S65L; S65T; Sapphire GFP; SBFI; Serotonin; Sevron 
Brilliant Red 2B; Sevron Brilliant Red 4G; Sevron I Brilliant 55 
Red B; Sevron Orange; Sevron Yellow L; sgBFP™ (super 
glow BFP); sgGFP™ (super glow GFP); SITS (Primuline; 
Stilbene Isothiosulphonic Acid); SNAFL calcein; SNAFL-1; 
SNAFL-2; SNARF calcein; SNARF I; Sodium Green; Spec-
trumAqua; SpectrumGreen; SpectrumOrange; Spectrum 60 
Red; SPQ (6-methoxy-N-(3 sulfopropyl) quinolinium); Stil-
bene; Sulphorhodamine B and C; Sulphorhodamine Extra; 
SYTO 11; SYTO 12; SYTO 13; SYTO 14; SYTO 15; SYTO 
16; SYTO 17; SYTO 18; SYTO 20; SYTO 21; SYTO 22; 
SYTO 23; SYTO 24; SYTO 25; SYTO 40; SYTO 41; SYTO 65 
42; SYTO 43; SYTO 44; SYTO 45; SYTO 59; SYTO 60; 
SYTO 61; SYTO 62; SYTO 63; SYTO 64; SYTO 80; SYTO 
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81; SYTO 82; SYTO 83; SYTO 84; SYTO 85; SYTOX Blue; 
SYTOX Green; SYTOX Orange; Tetracycline; Tetramethyl-
rhodamine (TRITC); Texas Red™; Texas Red-X™ conju-
gate; Thiadicarbocyanine (DiSC3 ); Thiazine Red R; Thiazole 
Orange; Thioflavin 5; Thioflavin S; Thioflavin TON; Thi-
olyte; Thiozole Orange; Tinopol CBS (Calcofluor White); 
TIER; TO-PR0-1; TO-PR0-3; TO-PR0-5; TOTO-I; TOT0-
3; TriColor (PE-Cy5); TRITC Tetramethy!Rodaminel-
soThioCyanate; True Blue; Tru Red; Ultralite; Uranine B; 
Uvitex SFC; wt GFP; WW 781; X-Rhodamine; XRITC; 
Xylene Orange; Y66F; Y66H; Y66W; Yellow GFP; YFP; 
YO-PR0-1; YO-PR03; YOYO-l;YOY0-3; Sybr Green; 
Thiazole orange (interchelating dyes); semiconductor nano-
particles such as quantum dots; or caged fluorophore (which 
can be activated with light or other electromagnetic energy 
source), or a combination thereof. 
In some embodiments, the fibrin knob peptides can be 
conjugated to a radionuclide (radioisotope). Radionuclides 
include, but are not limited to, tritium, iodine-125, iodine-
131, iodine-123, iodine-124, astatine-210, carbon-11, car-
bon-14, nitrogen-13, fluorine-18. The radionuclide can be 
attached to a linking group or bound by a chelating group, 
which is then attached to the peptide directly or by means of 
a linker. Radio labeling techniques such as these are routinely 
used in the radiopharmaceutical industry can be used. 
In some embodiments, the fibrin knob peptides can be 
conjugated to a contrast agent, such as those used for Mag-
netic resonance imaging (MRI), CT, PET, or ultrasound. 
MRI contrast agents alter the relaxation times of tissues 
and body cavities where they are present. Depending on the 
image weighting, this can give a higher or lower signal. The 
most commonly used compounds for MRI contrast enhance-
ment are gadolinium-based. Gadolinium-containing contrast 
agents include gadodiamide (OMNISCAN®), gadobenic 
acid (MULTIHANCE®), gadopentetic acid (MAGNEV-
IST®), gadoteridol (PROHANCE®), gadofosveset (ABLA-
VAR®), gadoversetamide (OPTIMARK®), gadoxetic acid 
(EOVIST®), gadobutrol, gadocoletic acid, gadodenterate, 
gadomelitol, gadopenamide, and gadoteric acid (DOT-
AREM®). Two types iron oxide contrast agents exist: Super-
paramagnetic Iron Oxide (SPIO) and Ultrasmall Superpara-
magnetic Iron Oxide (USPIO). These contrast agents consist 
of suspended colloids of iron oxide nanoparticles and when 
injected during imaging reduce the T2 signals of absorbing 
tissues. Available iron oxide contrast agents include Cliavist, 
COMBIDEX® (ferumoxtran-10), Endorem (FERIDEX 
IV®-ferumoxides injectable solution), Resovist, and 
Sinerem. Manganese chelates such as Mn-DPDP enhances 
the Tl signal. 
Ultrasound contrast agents rely on the different ways in 
which sound waves are reflected from interfaces between 
substances. This may be the surface of a small air bubble or a 
more complex structure. Commercially available contrast 
media are gas-filled micro bubbles that are administered intra-
venously to the systemic circulation. Microbubbles have a 
high degree of echogenicity, which is the ability of an object 
to reflect the ultrasound waves. The echogenicity difference 
between the gas in the microbubbles and the soft tissue sur-
roundings of the body is immense. Thus, ultrasonic imaging 
using microbubble contrast agents enhances the ultrasound 
backscatter, or reflection of the ultrasound waves, to produce 
a unique sonogram with increased contrast due to the high 
echogenicity difference. 
Therefore, in some embodiments, the fibrin knob peptides 
are conjugated to liposomes, micelles, or polymer nano-
pheres or microspheress. These agents can act as carriers of 
imaging elements, therapeutics, or a combination thereof. 
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C. Conjugation 
The disclosed fibrin knob peptides can be conjugated to the 
disclosed substances, such as peptides, proteins, or polymers 
using standard methods known in the art. Where the sub-
stance is a peptide/protein that peptide/protein is preferably in 5 
a fusion protein with the fibrin knob peptides. 
1. Fusion Proteins 
24 
Mo!. Cell. Biol., 11 :5848-5849 (1991 ); BiP protein (Macejak 
and Sarnow, Nature, 353:91 (1991)); the Antennapedia gene 
of drosophilia ( exons d and e) [Oh et al., Genes & Develop-
ment, 6: 1643-1653 (1992)); those in polio virus [Pelletier and 
Sonenberg, Nature, 334:320325 (1988); see also Mountford 
and Smith, TIG, 11:179-184 (1985)). 
2. Crosslinkers 
The disclosed fibrin knob peptides can be conjugated to the 
disclosed substances, such as peptides, proteins, or polymers 
using crosslinkers. Protein crosslinkers that can be used to 
crosslink substances to the disclosed fibrin knob peptides are 
known in the art and are defined based on utility and structure 
and include DSS (Disuccinimidylsuberate), DSP (Dithiobis 
(succinimidylpropionate )), DTSSP (3,3'-Dithiobis (sulfosuc-
cinimidylpropionate )), SULFO BSOCOES (Bis[2-(sulfosuc-
cinimdooxycarbonyloxy)ethyl]sulfone), BSOCOES (Bis[2-
Fusion proteins, also know as chimeric proteins, are pro- 10 
teins created through the joining of two or more genes which 
originally coded for separate proteins. Translation of this 
fusion gene results in a single polypeptide with function 
properties derived from each of the original proteins. Recom-
binant fusion proteins can be created artificially by recombi- 15 
nant DNA technology for use in biological research or thera-
peutics. Chimeric mutant proteins occur naturally when a 
large-scale mutation, typically a chromosomal translocation, 
creates a novel coding sequence containing parts of the cod-
ing sequences from two different genes. 
The functionality of fusion proteins is made possible by the 
fact that many protein functional domains are modular. In 
other words, the linear portion of a polypeptide which corre-
sponds to a given domain, such as a tyrosine kinase domain, 
may be removed from the rest of the protein without destroy- 25 
ing its intrinsic enzymatic capability. Thus, any of the herein 
disclosed functional domains can be used to design a fusion 
protein. 
20 (succinimdooxycarbonyloxy)ethyl]sulfone), SULFO DST 
(Disulthsuccinimdyltartrate ), DST (Disuccinimdyltartrate ), 
SULFO EGS (Ethylene glycolbis(succinimidylsuccinate)), 
EGS (Ethylene glycolbis(sulfosuccinimidylsuccinate )), 
A recombinant fusion protein is a protein created through 
genetic engineering of a fusion gene. This typically involves 30 
removing the stop codon from a cDNA sequence coding for 
the first protein, then appending the cDNA sequence of the 
second protein in frame through ligation or overlap extension 
PCR. That DNA sequence will then be expressed by a cell as 
a single protein. The protein can be engineered to include the 35 
full sequence of both original proteins, or only a portion of 
either. 
If the two entities are proteins, often linker (or "spacer") 
peptides are also added which make it more likely that the 
proteins fold independently and behave as expected. Espe- 40 
cially in the case where the linkers enable protein purification, 
linkers in protein or peptide fusions are sometimes engi-
neered with cleavage sites for proteases or chemical agents 
which enable the liberation of the two separate proteins. This 
technique is often used for identification and purification of 45 
proteins, by fusing a GST protein, FLAG peptide, or a hexa-
his peptide, which can be isolated using nickel or cobalt resins 
(affinity chromatography). 
Alternatively, internal ribosome entry sites (IRES) ele-
ments can be used to create multigene, or polycistronic, mes- 50 
sages. IRES elements are able to bypass the ribosome scan-
ning model of 5' methylated Cap dependent translation and 
begin translation at internal sites (Pelletier and Sonenberg, 
1988). IRES elements from two members of the picornavirus 
family (polio and encephalomyocarditis) have been 55 
described (Pelletier and Sonenberg, 1988), as well an IRES 
from a mammalian message (Macejak and Sarnow, 1991). 
IRES elements can be linked to heterologous open reading 
frames. Multiple open reading frames can be transcribed 
together, each separated by an IRES, creating polycistronic 60 
messages. By virtue of the IRES element, each open reading 
frame is accessible to ribosomes for efficient translation. 
Multiple genes can be efficiently expressed using a single 
promoter/enhancer to transcribe a single message (U.S. Pat. 
Nos. 5,925,565 and 5,935,819; PCT/US99/05781). IRES 65 
sequences are known in the art and include those from 
encephalomycarditis virus (EMCV) (Ghattas, I. R. et al., 
DPDPB (1,2-Di[3'-(2'-pyridyldithio) propionamido ]butane), 
BSSS (Bis(sulfosuccinimdyl)suberate), SMPB (Succinim-
dyl-4-(p-maleimidophenyl)butyrate), SULFO SMPB (Sulfo-
succinimdyl-4-(p-maleimidophenyl)butyrate), MBS (3-Ma-
leimidobenzoyl-N-hydroxysuccinimide ester), SULFO MBS 
(3-Maleimidobenzoyl-N-hydroxysulfosuccinimide ester), 
SIAB (N-Succinimidyl( 4-iodoacetyl)aminobenzoate ), 
SULFO SIAB (N-Sulfosuccinimidyl(4-iodoacetyl)ami-
nobenzoate), SMCC (Succinimidyl-4-(N-maleimidomethyl) 
cyclohexane-1-carboxylate ), SULFO SMCC (Sulfosuccin-
imidyl-4-(N-maleimidomethyl)cyclohexane-l-carboxylate ), 
NHS LC SPDP (Succinimidyl-6-[3-(2-pyridyldithio)propi-
onamido) hexanoate ), SULFO NHS LC SPDP (Sulfosuccin-
imidyl-6-[3-(2-pyridyldithio )propionamido) hexanoate ), 
SPDP (N-Succinimdyl-3-(2-pyridyldithio )propionate), NHS 
BROMOACETATE (N-Hydroxysuccinimidylbromoac-
etate), NHS IODOACETATE (N-Hydroxysuccinim-
idyliodoacetate ), MPBH ( 4-(N-Maleimidophenyl)butyric 
acid hydrazide hydrochloride), MCCH (4-(N-Maleimidom-
ethyl) cyclohexane-1-carboxylic acid hydrazide hydrochlo-
ride), MBH (m-Maleimidobenzoic acidhydrazidehydrochlo-
ride), SULFO EMCS(N-(epsilon-Maleimidocaproyloxy) 
sulfosuccinimide ), EMCS(N-( epsilon-
Maleimidocaproyloxy )succinimide ), PMPI (N-(p-
Maleimidophenyl) isocyanate), KMUH (N-(kappa-
Maleimidoundecanoic acid)hydrazide ), LC SMCC 
(Succinimidy 1-4-(N-maleimidomethy 1)-cyclohexane- l -car-
boxy( 6-amidocaproate) ), SULFO GMBS (N-(gamma-Male-
imidobutryloxy) sulfosuccinimide ester), SMPH (Succinim-
idyl-6-(beta-maleimidopropionamidohexanoate) ), SULFO 
KMUS (N-(kappa-Maleimidoundecanoyloxy)sulfosuccin-
imide ester), GMBS (N-(ganrma-Maleimidobutyrloxy)suc-
cinimide), DMP (Dimethylpimelimidate hydrochloride), 
DMS (Dimethylsuberimidate hydrochloride), MHBH 
(Wood's Reagent) (Methyl-p-hydroxybenzimidate hydro-
chloride, 98% ), DMA (Dimethyladipimidate hydrochloride). 
3. Multivalent Conjugation 
Two or more of the disclosed fibrin knob peptides can be 
conjugated together to form divalent or multivalent knob 
peptides where each of the fibrin knob peptides is at the 
N-terminus of its peptide chain. Thus, disclosed is a compo-
sition having the formula: 
US 8,513,380 B2 
25 
FKP-X-FKP I , 
y 
wherein FKP is a fibrin knob peptide, Xis a linker, and Y is a 
substance disclosed herein for conjugation to a fibrin knob 
peptide, such as a peptide, protein, or polymer. Thus also 
disclosed is a composition having the formula: 
FKP 
I 
FKP-X-FKP I , 
y 
wherein FKP is a fibrin knob peptide, Xis a linker, such as an 
amino acid linker, and Y is a substance disclosed herein for 
conjugation to a fibrin knob peptide, such as a peptide, pro-
tein, or polymer. Other such conjugations of fibrin knob pep-
tides can be envisioned and are disclosed. 
Thus, in some embodiments, the polypeptides are linked to 
form a dendrimer. Peptide dendrimers are branched, often 
highly branched, artificial proteins in which several peptide 
chains branch out from a dendritic core matrix that is built up 
through the propagation of, for example, a trifunctional 
amino acid, such as Lys. Originally conceived as Multiple 
Antigen Presentation System (MAPs) for vaccine develop-
ment, these molecules are also useful for protein design. 
The term "amino acid linker" refers to an amino acid 
sequences or insertion that can be used to connect or separate 
two distinct polypeptides or polypeptide fragments, wherein 
the linker does not otherwise contribute to the essential func-
tion of the composition. 
D. Nucleic Acids Encoding Fibrin Knobs 
Also disclosed are nucleic acids encoding the disclosed 
fibrin knob peptides and fusion proteins. Thus, disclosed are 
all nucleic acids, including degenerate nucleic acids, encod-
ing the disclosed variants and derivatives of the protein 
sequences. While each particular nucleic acid sequence may 
not be written out, it is understood that each and every 
sequence is in fact disclosed and described through the dis-
closed protein sequence. 
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HindIII E restriction fragment (Greenway, P. J. et al., Gene 
18: 355-360 (1982)). Of course, promoters from the host cell 
or related species can also be used. 
Enhancer generally refers to a sequence of DNA that func-
tions at no fixed distance from the transcription start site and 
can be either 5' (Laimins, L. et al., Proc. Natl. Acad. Sci. 78: 
993 (1981)) or 3' (Lusky, M. L., et al., Mo!. Cell. Bio. 3: 1108 
(1983)) to the transcription unit. Furthermore, enhancers can 
be within an intron (Banerji, J. L. et al., Cell 33: 729 (1983)) 
10 as well as within the coding sequence itself (Osborne, T. F., et 
al., Mo!. Cell. Bio. 4: 1293 (1984)). They are usually between 
10 and 300 bp in length, and they function in cis. Enhancers 
function to increase transcription from nearby promoters. 
Enhancers also often contain response elements that mediate 
15 the regulation of transcription. Promoters can also contain 
response elements that mediate the regulation of transcrip-
tion. Enhancers often determine the regulation of expression 
of a gene. While many enhancer sequences are now known 
from mammalian genes (globin, elastase, albumin, a-feto-
20 protein and insulin), typically one will use an enhancer from 
a eukaryotic cell virus for general expression. Preferred 
examples are the SV40 enhancer on the late side of the rep-
lication origin (bp 100-270), the cytomegalovirus early pro-
moter enhancer, the polyoma enhancer on the late side of the 
25 replication origin, and adenovirus enhancers. 
The promotor and/or enhancer may be specifically acti-
vated either by light or specific chemical events which trigger 
their function. Systems can be regulated by reagents such as 
tetracycline and dexamethasone. There are also ways to 
30 enhance viral vector gene expression by exposure to irradia-
tion, such as gamma irradiation, or alkylating chemotherapy 
drugs. 
In certain embodiments the promoter and/or enhancer 
region can act as a constitutive promoter and/or enhancer to 
35 maximize expression of the region of the transcription unit to 
be transcribed. In certain constructs the promoter and/or 
enhancer region be active in all eukaryotic cell types, even if 
it is only expressed in a particular type of cell at a particular 
time. A preferred promoter of this type is the CMV promoter 
40 (650 bases). Other preferred promoters are SV40 promoters, 
cytomegalovirus (full length promoter), and retroviral vector 
LTR. 
The nucleic acids that are delivered to cells typically con- 45 
tain expression control systems. For example, the inserted 
genes in viral and retroviral systems usually contain promot-
ers, and/or enhancers to help control the expression of the 
desired gene product. A promoter is generally a sequence or 
sequences of DNA that function when in a relatively fixed 50 
location in regard to the transcription start site. A promoter 
contains core elements required for basic interaction of RNA 
polymerase and transcription factors, and may contain 
upstream elements and response elements. Thus, also dis-
closed are nucleic acids encoding the disclosed polypeptides 55 
operably linked to an expression control sequence. 
It has been shown that all specific regulatory elements can 
be cloned and used to construct expression vectors that are 
selectively expressed in specific cell types such as melanoma 
cells. The glial fibrillary acetic protein (GFAP) promoter has 
been used to selectively express genes in cells of glial origin. 
Expression vectors used in enkaryotic host cells (yeast, 
fungi, insect, plant, animal, human or nucleated cells) may 
also contain sequences necessary for the termination of tran-
scription which may affect mRNA expression. These regions 
are transcribed as polyadenylated segments in the untrans-
lated portion of the mRNA encoding tissue factor protein. The 
3' untranslated regions also include transcription termination 
sites. It is preferred that the transcription unit also contain a 
polyadenylation region. One benefit of this region is that it 
Preferred promoters controlling transcription from vectors 
in mammalian host cells may be obtained from various 
sources, for example, the genomes of viruses such as: 
polyoma, Simian Virus 40 (SV40), adenovirus, retroviruses, 60 
hepatitis-B virus and most preferably cytomegalovirus, or 
from heterologous mammalian promoters, e.g. beta actin pro-
moter. The early and late promoters of the SV 40 virus are 
conveniently obtained as an SV 40 restriction fragment which 
also contains the SV 40 viral origin of replication (Fiers et al., 65 
Nature, 273: 113 (1978)). The immediate early promoter of 
the human cytomegalovirus is conveniently obtained as a 
increases the likelihood that the transcribed unit will be pro-
cessed and transported like mRNA. The identification and use 
of polyadenylation signals in expression constructs is well 
established. It is preferred that homologous polyadenylation 
signals be used in the transgene constructs. In certain tran-
scription units, the polyadenylation region is derived from the 
SV 40 early polyadenylation signal and contains of about 400 
bases. It is also preferred that the transcribed units contain 
other standard sequences alone or in combination with the 
above sequences improve expression from, or stability of, the 
construct. 
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A vector containing a nucleic acid encoding the disclosed 
polypeptides is also disclosed. In some embodiments the 
vector is derived from either a virus or a retrovirus. Viral 
vectors are, for example, Adenovirus, Adena-associated 
virus, Herpes virus, Vaccinia virus, Polio virus, AIDS virus, 
neuronal trophic virus, Sindbis and other RNA viruses, 
including these viruses with the HIV backbone. Also pre-
ferred are any viral families which share the properties of 
these viruses which make them suitable for use as vectors. 
Retroviruses include Murine Maloney Leukemia virus, 
MMLV, and retroviruses that express the desirable properties 
microsurgical anastomoses and skin graft adhesion. Using 
fibrin glue instead of sutures or staples enhances healing, 
minimizes scarring, eases application and in the case of her-
nia repair lowers the risk of nerve injury and postoperative 
neuralgia. Fibrin glue has also been shown to be effective in 
helping to anchor a deep brain stimulation electrode for the 
treatment of Parkinson's disease by acting as a protective 
layer between the dura and the methyl methacrylate bioglue 
that anchors the upper portion of the electrode to a stabilized 
10 titanium plate. 
of MMLV as a vector. Retroviral vectors are able to carry a 
larger genetic payload, i.e., a transgene or marker gene, than 
other viral vectors, and for this reason are a commonly used 
vector. However, they are not as useful in non-proliferating 15 
cells. Adenovirus vectors are relatively stable and easy to 
work with, have high titers, and can be delivered in aerosol 
formulation, and can transfect non-dividing cells. Pox viral 
vectors are large and have several sites for inserting genes, 
they are thermostable and can be stored at room temperature. 20 
A preferred embodiment is a viral vector which has been 
engineered so as to suppress the immune response of the host 
organism, elicited by the viral antigens. 
2. Drug Delivery 
To provide injury repair, it is often desirable to locally 
deliver tissue-specific growth factors in a controlled manner. 
Fibrin is an appealing drug delivery vehicle because it can be 
injected where it gels in situ, it is degraded naturally and it 
stimulates the body's own wound healing response. By modi-
fying the interaction between the growth factor and the fibrin 
scaffold, it is possible to vary the release profile from hours to 
weeks. The release rate is dependent upon the growth factor's 
initial concentration, diffusion rate and interaction with the 
matrix. Increasing the fibrinogen concentration would reduce Cells containing one or more of the disclosed nucleic acids 
or vectors are also disclosed. 
E. Fibrin Gels 
25 the matrix pore size and thus retard the permeation of large 
solutes; however, increasing the concentration also retards 
endothelial cell migration and capillary formation. The fibrin knob peptides can be used in the formation of 
fibrin polymer gels. Therefore, fibrin gels that contain fibrin 
knob peptides conjugated to a substance disclosed herein are 
provided. In a preferred embodiment, the fibrin polymer is a 30 
hydrogel. Hydrogels can exhibit dramatic effects of swelling 
or shrinking upon a stimulus. One such stimulus is movement 
or conformational change of biomolecules attached thereto. 
Another type of stimulus occurs when there is a change in pH 
3. Cell Delivery 
Growth factor delivery is sufficient only ifthere are cells in 
the injury area capable of responding to the signals. When 
defects exceed a critical size, the local cell population is not 
sufficient to repair the injury and additional cells must be 
introduced. This is another application where fibrin has 
proven useful. Keratinocytes suspended in fibrin can be effec-
tive in reconstituting full thickness wounds, while skin fibro-
blast-coated fibrin microbeads can decrease the time for 
granulation tissue formation. 
In plastic surgery, fat tissue transplantation is often 
required to create the desired look but this process can result 
in donor site deformity and also a gradual resorption of the 
transplanted tissue. Preadipocyte-seeded fibrin is possible 
alternative to autologous tissue transplantation. Injecting 
skeletal myoblasts in a fibrin scaffold into infarct regions of 
the heart can also improve cell survival and reduced the 
infarct scar. In this setting, the elastic modulus of the scaffold 
may be of particular significance since myocyte development 
does not proceed normally on materials with abnormally high 
in the environment in which the hydrogel is present. Such 35 
local pH change causes water and counter-ions to move in or 
out of the hydrogel and this induces swelling or shrinking of 
the hydrogel. Certain types of hydrogels undergo abrupt 
changes in volume in response to changes in pH, temperature, 
electric fields, saccharides, antigens and solvent composition, 40 
among others. Natural and artificial hydrogels can also be 
forced to shrink or swell by applying a bias on a metal elec-
trode underneath or embedded in a hydro gel gel. Generally, a 
hydrogel can be prepared using many suitable monomers 
that, when polymerized, forms a hydro gel, such as acrylates, 45 
acrylamides, acetates, acrylic acids, vinyl alcohols, and gly-
cols. Therefore, in some embodiments, the disclosed fibrin 
gel also contains at least one other monomer suitable for 
preparation of a hydrogel, such as acrylates, acrylamides, 
acetates, acrylic acids, vinyl alcohols, and glycols. 50 stiffness. 
Fibrin polymers formed using the disclosed fibrin knob 
peptides, and conjugates thereof, have many clinical and 
bioengineering uses. 
4. Cell Differentiation and Tissue Engineering 
Unlike a synthetic hydro gel, fibrin is not just a passive cell 
1. Haemostatic Glue and Wound Repair 55 delivery matrix, but it binds specifically many growth factors 
as well as clot components, such as fibronectin, hyaluronic 
acid and von Wille brand factor. This bioactivity makes fibrin 
an attractive matrix for stem cell differentiation and tissue 
Fibrin glue is currently being used clinically as an adjunct 
therapy to stem bleeding and to replace sutures in certain 
applications. Since the blood comes from a common pool, 
there is a risk of disease or prion transmission, even though 60 
the solutions are carefully processed and screened. To avoid 
this risk, researchers have developed systems to concentrate 
autologous fibrin glue from a patient's serum. To ensure that 
clotting occurs quickly and effectively, fibrin glues usually 
contain very high amounts of fibrinogen and thrombin. Cur- 65 
rent clinical uses include mesh fixation for inguinal hernia 
repair, severed sciatic nerve reattachment, stabilization of 
engineering. Fibrin has been effective as a scaffold for carti-
lage, cardiovascular and nervous tissue engineering. In carti-
lage tissue engineering, fibrin promotes glycosaminoglycan 
and collagen II while inhibiting collagen I deposition by 
primary or stem cell-derived chondrocytes. This trend is fur-
ther enhanced by adding hyaluronic acid to the gel. To 
enhance the strength of the fibrin gel, a combination strategy 
can be employed whereby a highly porous synthetic polymer 
scaffold with appropriate mechanical properties is filled with 
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chondrocytes suspended in a fibrin gel and this whole con-
struct is implanted at the desired junction. 
Severed peripheral nerve axons have some capacity to 
repair themselves but only if the defect is below a certain 
critical length. Fibrin sealant can be used for promoting nerve 
repair for a long time. To promote regeneration over longer 
lengths, channels filled with stimulatory signals can be used 
to bridge the severed ends. Synthetic polymer channels filled 
with fibrin can improve nerve repair and this is further 
enhanced if Schwarm cells, which bind fibrin through av~S 
integrins and are required for healthy axon development, are 
suspended in the fibrin. 
In addition to its central role in haemostasis, the fibrin clot 
also serves as a scaffold for angiogenesis. This makes fibrin 
uniquely suited for cardiovascular tissue engineering. As with 
cartilage and nerve regeneration, the best results are achieved 
when a synthetic scaffold with the desired mechanical prop-
erties is combined with a biologically tuned fibrin gel. One of 
the most advanced applications of a fibrin gel in cardiovas-
cular engineering is the development of a moulding system to 
produce tricuspid heart valve replacements from fibrin, fibro-
blasts and smooth muscle myocytes. 
5. Patterning 
An increasingly common method to pattern tissue equiva-
lents is by culturing them in a bioreactor. The bioreactors are 
individually designed to apply physiologically relevant 
forces to precondition the implants for their in vivo applica-
tion. Grafts can be patterned by orienting the fibrin fibrils as 
they are polymerizing, which results in an anisotropic struc-
ture independent of applied force. This can be done by con-
trolling the initiation sites, polymerizing fibrin under flow or 
in a high magnetic field or by electro spinning the protein on to 
a rotating target. Aligned fibrin has been shown to enhance 
neurite alignment and could be a useful filler for nerve guid-
ance channels. Electrospinning has the added advantage of 
being able to design more advanced patterns, such as cross-
hatching, by manipulating the electric field. Control of solu-
tion conditions can also control fiber thickness and therefore 
permeability through the matrix. 
F. Combination Therapies 
A composition that contains the disclosed fibrin knob pep-
tides, and conjugates thereof, and any known or newly dis-
covered substance that can be administered to sites of fibrin 
formation are also disclosed. 
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Benzydamine Hydrochloride, Bromelains, Broperamole, 
Budesonide, Carprofen, Cicloprofen, Cintazone, Cliprofen, 
Clobetasol Propionate, Clobetasone Butyrate, Clopirac, 
Cloticasone Propionate, Cormethasone Acetate, Cortodox-
one, Decanoate, Deflazacort, Delatestryl, Depa-Testoster-
one, Desonide, Desoximetasone, Dexamethasone Dipropi-
onate, Diclofenac Potassium, Diclofenac Sodium, 
Diflorasone Diacetate, Diflumidone Sodium, Diflunisal, Dif-
luprednate, Diftalone, Dimethyl Sulfoxide, Drocinonide, 
10 Endrysone, Enlimomab, Enolicam Sodium, Epirizole, Etod-
olac, Etofenamate, Felbinac, Fenamole, Fenbufen, Fen-
clofenac, Fenclorac, Fendosal, Fenpipalone, Fentiazac, 
Flazalone, Fluazacort, Flufenamic Acid, Flumizole, 
FlunisolideAcetate, Flunixin, Flunixin Meglumine, Fluocor-
15 tin Butyl, Fluorometholone Acetate, Fluquazone, Flurbipro-
fen, Fluretofen, Fluticasone Propionate, Furaprofen, 
Furobufen, Halcinonide, Halobetasol Propionate, Halopre-
done Acetate, Ibufenac, Ibuprofen, Ibuprofen Aluminum, 
Ibuprofen Piconol, Ilonidap, Indomethacin, Indomethacin 
20 Sodium, Indoprofen, Indoxole, Intrazole, Isoflupredone 
Acetate, Isoxepac, Isoxicam, Ketoprofen, Lofemizole 
Hydrochloride, Lomoxicam, Loteprednol Etabonate, 
Meclofenamate Sodium, Meclofenamic Acid, Meclorisone 
Dibutyrate, Mefenamic Acid, Mesalamine, Meseclazone, 
25 Mesterolone, Methandrostenolone, Methenolone, Meth-
enoloneAcetate, Methylprednisolone Suleptanate, Momiflu-
mate, Nabumetone, Nandrolone, Naproxen, Naproxen 
Sodium, Naproxol, Nimazone, Olsalazine Sodium, Orgotein, 
Orpanoxin, Oxandrolane, Oxaprozin, Oxyphenbutazone, 
30 Oxymetholone, Paranyline Hydrochloride, Pentosan 
Polysulfate Sodium, Phenbutazone Sodium Glycerate, Pir-
fenidone, Piroxicam, Piroxicam Cinnamate, Piroxicam Ola-
mine, Pirprofen, Prednazate, Prifelone, Prodolic Acid, Pro-
quazone, Proxazole, Proxazole Citrate, Rimexolone, 
35 Romazarit, Salcolex, Salnacedin, Salsalate, Sanguinarium 
Chloride, Seclazone, Sermetacin, Stanozolol, Sudoxicam, 
Sulindac, Suprofen, Talmetacin, Talniflumate, Talosalate, 
Tebufelone, Tenidap, Tenidap Sodium, Tenoxicam, Tesicam, 
Tesimide, Testosterone, Testosterone Blends, Tetrydamine, 
40 Tiopinac, Tixocortol Pivalate, Tolmetin, Tolmetin Sodium, 
Triclonide, Triflumidate, Zidometacin, Zomepirac Sodium). 
The provided composition(s) can further include one or 
more of classes of anti-histaminic agents (e.g., Ethanola-
mines (like diphenhydrmine carbinoxamine), Ethylenedi-
45 amine (like tripelennamine pyrilamine), Alkylamine (like 
chlorpheniramine, dexchlorpheniramine, brompheniramine, 
triprolidine ), other anti-histamines like astemizole, lorata-
dine, fexofenadine, Bropheniramine, Clemastine, Acetami-
For example, the provided composition(s) can further 
include one or more of classes of antibiotics (e.g., Aminogly-
cosides, Cephalosporins, Chloramphenicol, Clindamycin, 
Erythromycins, Fluoroquinolones, Macrolides, Azolides, 50 
Metronidazole, Penicillins, Tetracyclines, Trimethoprim-sul-
famethoxazole, Vancomycin). 
nophen, Pseudoephedrine, Triprolidine ). 
G. Pharmaceutical Compositions 
The compositions disclosed can be used therapeutically in 
combination with a pharmaceutically acceptable excipient/ 
carrier. Thus, also disclosed is a pharmaceutical composition 
having an effective amount of one or more polypeptides dis-
The provided composition(s) can further include one or 
more of classes of steroids (e.g., Andranes (e.g., Testoster-
one). 
The provided composition(s) can further include one or 
more of classes of narcotic and non-narcotic analgesics (e.g., 
Morphine, Codeine, Heroin, Hydromorphone, Levorphanol, 
Meperidine, Methadone, Oxydone, Propoxyphene, Fentanyl, 
Methadone, Naloxone, Buprenorphine, Butorphanol, Nalbu-
phine, Pentazocine ). 
The provided composition(s) can further include one or 
more of classes of anti-inflammatory agents ( e.g.,Alclofenac, 
Alclometasone Dipropionate, Algestone Acetonide, alpha 
Amylase, Amcinafal, Amcinafide, Amfenac Sodium, Ami-
prilose Hydrochloride, Anakinra, Anirolac, Anitrazafen, 
Apazone, Balsalazide Disodium, Bendazac, Benoxaprofen, 
55 closed herein and a pharmaceutically acceptable excipient. 
Pharmaceutical excipients are known to those skilled in the 
art. These most typically would be standard carriers for 
administration of drugs to humans, including solutions such 
as sterile water, saline, and buffered solutions at physiological 
60 pH. Pharmaceutical compositions may include carriers, 
thickeners, diluents, buffers, preservatives, surface active 
agents and the like in addition to the active agent. Pharma-
ceutical compositions may also include one or more active 
ingredients such as antimicrobial agents, anti-inflammatory 
65 agents, anesthetics, and the like. 
Suitable pharmaceutical preparations include sterile aque-
ous or non-aqueous solutions, suspensions, and emulsions. 
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Examples of non-aqueous solvents are propylene glycol, 
polyethylene glycol, vegetable oils such as olive oil, and 
injectable organic esters such as ethyl oleate. Aqueous carri-
ers include water, alcoholic/aqueous solutions, emulsions or 
suspensions, including saline and buffered media. Parenteral 
vehicles include sodium chloride solution, Ringer's dextrose, 
dextrose and sodium chloride, lactated Ringer's, or fixed oils. 
Intravenous vehicles include fluid and nutrient replenishers, 
electrolyte replenishers (such as those based on Ringer's 
dextrose), and the like. Preservatives and other additives may 
also be present such as, for example, antimicrobials, anti-
oxidants, chelating agents, and inert gases and the like. 
Suitable formulations include sprays, liquids and powders. 
Conventional pharmaceutical carriers, aqueous, powder or 
oily bases, thickeners and the like may be necessary or desir-
able. Compositions for oral administration include powders 
or granules, suspensions or solutions in water or non-aqueous 
media, capsules, sachets, or tablets. Thickeners, flavorings, 
diluents, emulsifiers, dispersing aids or binders may be desir-
able. 
Some of the compositions may potentially be administered 
as a pharmaceutically acceptable acid- or base-addition salt, 
formed by reaction with inorganic acids such as hydrochloric 
acid, hydrobromic acid, perchloric acid, nitric acid, thiocya-
nic acid, sulfuric acid, and phosphoric acid, and organic acids 
such as formic acid, acetic acid, propionic acid, glycolic acid, 
lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic 
acid, maleic acid, and fumaric acid, or by reaction with an 
inorganic base such as sodium hydroxide, ammonium 
hydroxide, potassium hydroxide, and organic bases such as 
mono-, di-, trialkyl and aryl amines and substituted ethano-
lamines. 
III. METHODS 
A. Method of Targeting an Agent to Fibrin 
Methods are disclosed for targeting an agent, such as a 
peptide, molecule, or polymer, to fibrinogen or fibrin within a 
subject. For example, the method can involve administering 
to a subject a pharmaceutical composition that includes a 
fibrin knob peptide conjugated to a substance in a pharma-
ceutically acceptable carrier. As a result of this method, the 
substance conjugated to the fibrin knob peptide will bind via 
the fibrin knob peptide to fibrinogen or fibrin within the 
subject. This has many therapeutic and diagnostic uses. 
1. Method of Diagnosing and Treating Clots 
The ability of a fibrin knob peptide to bind and integrate 
into fibrin polymers indicates a use for these peptides to detect 
clots in a subject. Coagulation is an important part ofhemo-
stasis (the cessation of blood loss from a damaged vessel), 
wherein a damaged blood vessel wall is covered by a platelet 
and fibrin-containing clot to stop bleeding and begin repairof 
the damaged vessel. 
Therefore, a method is provided for detecting fibrin-con-
taining clots in a subject that involves administering to the 
subject a fibrin knob peptide conjugated to a label. In this 
method, the fibrin knob peptide conjugate will bind in a 
dose-dependent manner to the fibrin-containing clot and the 
label will subsequently concentrate at that location. 
In some embodiments, the fibrin knob peptide is conju-
gated to an anti-coagulant to break up the clot upon binding. 
2. Method of Diagnosing and Treating Fibrotic 
Disorders 
Fibrosis and/or fibrotic disorders are characterized by 
excessive deposition of extracellular matrix (ECM) proteins, 
32 
most notably members of the collagen family. The resultant 
dense ECM can restrict physiological functions, such as inha-
lation of the lung, or act to bind tissues which can restrict their 
motion and function, such as in the case of postoperative 
adhesions. There exist a multitude of pathologies that exhibit 
features of fibrosis and taken together these pathologies chal-
lenge all cancers as the leading cause of death in the U.S. 
Unfortunately there are no known cures of fibrosis and very 
few commercially available products that address the early 
10 stages of progression. The general lack of effective products 
may be due to fact that the exact mechanisms of each fibrotic 
response are unknown and likely differ. However, there do 
exist common pathways and regulators that have been deter-
mined and research is underway to target these common 
15 pathways. One such pathway is the persistence of fibrin. If 
normal fibrinolytic mechanisms are perturbed, resulting in 
the persistence of fibrin polymer, fibrosis displays a higher 
occurrence. Thus, technologies that target fibrin formation 
and/or fibrinolysis have demonstrated a level of success in 
20 combating fibrotic responses. 
Therefore, a method is provided for detecting fibrotic dis-
orders in a subject that involves administering to the subject a 
fibrin knob peptide. Methods are also provided for treating 
fibrotic disorders in a subject by administering to the subject 
25 a fibrin knob peptide conjugated to a substance that, for 
example, disrupts fibrin polymerization, inhibits fibrin poly-
mer stability, or promotes fibrinolysis. 
Pulmonary fibrosis is exceptionally insidious. The archi-
tecture and mechanics of the mature organ make it exception-
30 ally prone to rapid progression of fibrosis. Following a posi-
tive diagnosis, usually the presence of a nodule of dense, 
highly proliferative fibroblasts in biopsies, patients normally 
display a life expectancy of only 4 years. Recent studies 
indicate a rapid increase (over 150%) in the incidence of the 
35 disease over the past three years, further underscoring the 
importance of developing effective treatments for this deadly 
disease. There is no one universally accepted treatment for 
pulmonary fibrosis and no commercially available product 
has demonstrated a proven benefit and therefore the FDA has 
40 declared pulmonary fibrosis an orphan indication in hopes of 
promoting translational efforts. 
Therefore, a method is provided for detecting pulmonary 
fibrosis in a subject that involves administering to the subject 
a fibrin knob peptide conjugated to a label. In this method, the 
45 fibrin knob peptide conjugate will bind in a dose-dependent 
manner to the fibrin in the ECM of the lung and the label will 
subsequently concentrate at that location. 
In some embodiments, the fibrin knob peptides are conju-
gated to an inert carrier that can sterically hinder fibrin poly-
50 merization. For example, the fibrin knob peptides can be 
conjugated to polyethylene glycol (single- or multi-arm). In 
other embodiments, the fibrin knob peptides are conjugated to 
an enzyme that can improve local fibrinolytic activity. For 
example, the fibrin knob peptides can be conjugated (e.g., in 
55 a fusion protein) to tissue plasminogen activator (tPA). tPA is 
used in diseases that feature blood clots, such as pulmonary 
embolism, myocardial infarction and stroke, in a medical 
treatment called thrombolysis. To be effective in ischemic 
stroke, tPA must be administered within the first three hours 
60 of the event to be given intravenously, or within six hours to be 
administered through an arterial catheter directly to the site of 
occlusion. 
65 
B. Method of Treating a Wound 
Methods are disclosed for controlling bleeding and 
improving wound healing in a subject. Approaches for con-
US 8,513,380 B2 
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trolling bleeding, binding tissues, and inducing tissue regen-
eration are significantly needed in surgery, trauma, and emer-
gency response medicine. Substantial efforts to develop 
polymer systems addressing these needs have produced 
numerous products, yet in most cases such engineered poly-
mers have not performed better than the body's own hemo-
static/tissue sealant system, fibrinogen/fibrin. The fibrinogen/ 
fibrin system is useful as a surgical sealant because it rapidly 
34 
Other substances can be conjugated to the fibrin knob 
peptides to alter other properties, such as the regenerative 
potential of the fibrin glue/hydrogel. For example, growth 
factors conjugated to the fibrin knob peptides can in some 
embodiments promote tissue growth 
D. Method of Making Fibrin Knob Peptides 
forms an insoluble network that prevents blood loss following 10 Peptides or polypeptides can be chemically synthesized 
using currently available laboratory equipment using either 
Fmoc (9-fluorenylmethyloxycarbonyl) or Boe (tert-buty-
loxycarbonoyl) chemistry. (Applied Biosystems, Inc., Foster 
City, Calif.). One skilled in the art can readily appreciate that 
a peptide or polypeptide corresponding to the disclosed pro-
teins, for example, can be synthesized by standard chemical 
vascular injury and it effectively binds or' glues' tissues when 
used at high concentrations. However, its main advantages as 
a rapidly forming sealant also represent its principal short-
comings. Clinically useful formulations of fibrin-based sys- 15 
terns are orders of magnitude more concentrated than native 
circulating fibrinogen, and they polymerize into fiber net-
works whose extreme density prevent adjacent tissues from reactions. For example, a peptide or polypeptide can be syn-thesized and not cleaved from its synthesis resin whereas the 
remodeling them in normal, regenerative processes. Many 
20 previous strategies in regenerative medicine that have relied 
other fragment of a peptide or protein can be synthesized and 
subsequently cleaved from the resin, thereby exposing a ter-
minal group which is functionally blocked on the other frag-
ment. By peptide condensation reactions, these two frag-
ments can be covalently joined via a peptide bond at their 
on commercially available fibrin scaffolds (e.g. TISSEEL 
VH, Baxter) have generated inconsistent results because 
although these polymer systems support the mechanical loads 
necessary for a tissue sealant, they are biochemically 'non-
specific' and induce hyperproliferation and scar formation. 
Moreover they are physically 'nonpermissive' and prevent 
the angiogenic vascular invasion necessary for tissue regen-
eration. Addressing these significant shortcomings in an oth-
erwise promising clinical biomaterial requires new strategies 
for separating out and independently tuning both the bio-
chemical properties of fibrin and the physical characteristics 
of fibrin's polymerized matrices. 
A method is therefore disclosed for inducing, promoting, 
25 carboxyl and amino termini, respectively, to form an anti-
body, or fragment thereof. (Grant Ga. (1992) Synthetic Pep-
tides: A User Guide. W.H. Freeman and Co., N.Y. (1992); 
Bodansky Mand Trost B., Ed. (1993) Principles of Peptide 
Synthesis. Springer-Verlag Inc., NY (which is herein incor-
30 porated by reference at least for material related to peptide 
synthesis). Alternatively, the peptide or polypeptide is inde-
pendently synthesized in vivo as described herein. Once iso-
lated, these independent peptides or polypeptides may be 
linked to form a peptide or fragment thereof via similar pep-
35 tide condensation reactions. 
or enhancing fibrin clot formation in a subject. The method 
can involve administering to the subject a composition that 
includes a fibrin knob peptide conjugated to a substance that 
promotes wound healing. For example, the fibrin knob pep-
tide can be conjugated (e.g., as a fusion protein) to a growth 40 
factor that promotes wound healing. 
For example, enzymatic ligation of cloned or synthetic 
peptide segments allow relatively short peptide fragments to 
be joined to produce larger peptide fragments, polypeptides 
or whole protein domains (Abrahmsen Let al., Biochemistry, 
30:4151 (1991)). Alternatively, native chemical ligation of 
synthetic peptides can be utilized to synthetically construct 
The method can involve administering to the subject a 
composition that includes a fibrin knob peptide conjugated to 
an inert carrier that sterically hinders fibrin polymerization 
and/or destabilizes the polymer once formed. In 
In some embodiments, the method inhibits hemorrhage. In 
some embodiments, the method inhibits post-surgical adhe-
sion. In some embodiments, the method inhibits scar forma-
tion. In some embodiments, the method increase would clo-
sure. 
C. Method of Modulating Fibrin Glue Properties 
large peptides or polypeptides from shorter peptide frag-
ments. This method consists of a two step chemical reaction 
45 (Dawson et al. Synthesis of Proteins by Native Chemical 
Ligation. Science, 266:776-779 (1994)). The first step is the 
chemoselective reaction of an unprotected synthetic peptide-
thioester with another unprotected peptide segment contain-
ing an amino-terminal Cys residue to give a thioester-linked 
50 intermediate as the initial covalent product. Without a change 
in the reaction conditions, this intermediate undergoes spon-
taneous, rapid intramolecular reaction to form a native pep-
tide bond at the ligation site (Baggiolini Met al. (1992) FEBS 
55 
Lett. 307:97-101; Clark-Lewis I et al., J. Biol. Chem., 269: 
16075 (1994); Clark-Lewis I et al., Biochemistry, 30:3128 
(1991); Rajarathnam K et al., Biochemistry 33:6623-30 
(1994)). 
Methods are disclosed for modulating the properties of a 
fibrin glue for therapeutic use. For example, methods are 
provided for introducing fibrin knob-containing peptides into 
fibrin glue that alters the physical prosperities of the fibrin 
glue. Generally, the physical properties of the glue are modi- 60 
fied based on the substance conjugated to the fibrin knob 
peptides. 
Alternatively, unprotected peptide segments are chemi-
cally linked where the bond formed between the peptide 
segments as a result of the chemical ligation is an unnatural 
(non-peptide) bond (Schnolzer, M et al. Science, 256:221 
(1992)). This technique has been used to synthesize analogs 
of protein domains as well as large amounts of relatively pure 
For example, fibrin knob peptides conjugated to PEG can 
be used to alter the physical properties of the resulting fibrin 
glue/hydro gel. In some embodiments, the PEG concentration 
and degree of branching can alter the ability of cells, includ-
ing blood vessels, to invade the gel. 
65 proteins with full biological activity ( deLisle Milton R C et 
al., Techniques in Protein Chemistry IV. Academic Press, 
New York, pp. 257-267 (1992)). 
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EXAMPLES 
Example 1 
Recombinant Fusion Protein Production 
Materials and Methods 
Modification of Bacterial Expression Vector 
The original thrombincleavage site in the pGEX4T-1 vec-
tor (GE Healthcare, Piscataway, N.J.) was modified from 
LVPRtGSPE (SEQ ID N0:14) to LVPRtGPRV (SEQ ID 
N0:15), LVPRtGPRP (SEQ ID N0:16) and LVPRtGHRP 
(SEQ ID NO: 17) using the QuikChange® II-E Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, Calif.). All plasmids 
were introduced to and maintained in the electro-competent 
XL-1 Blue E. coli strain provided and cultured in LB+ ampi-
cillin plates at 37° C. Plasmids were extracted from cultures 
using the QIAquick Spin Miniprep Kit (QIAGEN, Valencia, 
Calif.) and verified via sequencing (Johns Hopkins Synthesis 
& Sequencing Facility, Baltimore, Md.). 
Amplification and Insertion ofFnIII9_10 into 
Expression Vectors 
Fibronectin's cell-binding 9th and lO'h type III repeats 
(FnIII9_10) was used as our model protein. The Sall site in the 
multiple cloning site (MCS) was used to insert the FnIII9_10 
open reading frame into the pGEX4TGSFD pGEX4TGPRV' 
pGEX4T GPRP and pGEX4T GHRP vectors obtained above 
using standard molecular cloning techniques (enzymes pur-
chased from NEB, Ipswich, Mass.). Briefly, the FnIII9_10 
open reading frame was amplified in a high fidelity poly-
merase chain reaction with Phusion High Fidelity DNA poly-
merase from the previously established pGEX4T-1-FnIII9_10 
plasmid (Martino MM, et al. Biomaterials 2009, 30(6):1089-
1097) using primers with flanking Sall sequences (under-
lined) and introducing Gly-Gly-Cys (bold) on the C-terminal 
if necessary: ACTGGTCGACTG GGTCTTGATTC-
CCCAACT (SEQ ID NO: 12) and ACTG 
GTCGACTCAGCAACCACCTGTTCGGTAATTAATGGA 
(SEQ ID NO: 13). Vectors and insert were digested with Sall. 
The vectors were additionally dephosphorylated using heat-
deactivate-able Antartic phosphatase to prevent self-ligation. 
The respective vectors and insert were ligated using T 4 DNA 
Ligase and transformed into electro-competent XL-1 Blue 
cells. Selection for successfully ligated plasmids containing 
the insert was made on LB+ ampicillin plates. The orientation 
of the FnIII9_10 insert was verified by in-colony PCR-screen-
ing using forward or reverse primers on the plasmid in com-
bination with an internal primer within the insert. Colonies 
with the insert in the correct orientation were grown up for 
plasmid extraction. All plasmids were verified via sequenc-
ing. 
Protein Production and Purification 
36 
X and 10 U/mL ofDNase was added and the lysate further 
incubated for 30 min with gentle agitation. The cell lysate was 
cleared of cellular debris by centrifugation followed by fil-
tration through a 0.22 µm pore filter. Purification of the 
5 recombinant proteins was performed following the manufac-
turer's recommendation using AKTAFPLC™ with a GST 
Prep FF 16/10 column (GE Healthcare) for affinity purifica-
tion ofGST-tagged proteins. Washing and binding steps were 
done in filter-sterilized PBS and elution completed with glu-
10 tathione (GSH) buffer (50 mM Tris-HCl, 10 mM reduced 
GSH, pH 8.0). The GSH buffer was then exchanged to PBS 
using an Amicon Ultra-15 centrifugal filter with MWCO 
10,000 (Millipore, Billerica, Mass.). The GST-tagged protein 
was incubated overnight with bovine thrombin (MP Biomedi-
cals, Solon, Ohio) dosed at 10 U per mg recombinant protein 
15 and the cleaved protein solution was reintroduced on the GST 
Prep FF 16/ 10 colunm to remove the GS Ttag, followed by the 
HiTrap Benzamidine FF colunm (GE Healthcare) to remove 
thrombin. Gxxx-FnIII9_10-(C) (SEQ ID N0:20) proteins 
were assessed for purity by SDS-PAGE and quantitated at 
20 Abs280 nm using the Nanodrop 1000 (Thermo Scientific, 
Wilmington, Del.) using extinction coefficients calculated 
using an online peptide property calculator (found at http:// 
www.basic.northwestentedu/biotools/proteincalc.html), 
then aliquoted and stored at -80° C. until use. 
25 Results 
An expression vector system allowing the simple and rapid 
cloning of any gene-of-interest into a series of vectors was 
developed thereby enabling the creation of any desired pro-
tein endowed with an N-terminal fibrin knob sequence. The 
30 
pGEX4T-1 expression vector allows the expression of pro-
teins with an N-terminal 26 kDa GST tag. This tag can then be 
removed via thrombin cleavage, analogous to the process of 
fibrinogen activation wherein protein segments are cleaved 
from the N-termini of the Aa- and B~-chains. Using the 
original pGEX4T-1 vector, the N-terminal sequence exposed 
35 upon thrombin cleavage of the GST-tagged protein is GSPE 
(Gly-Ser-Pro-Glu, SEQ ID NO:l 1), which does not bind to 
fibrin pockets. The corresponding coding sequence on the 
expression vector to each of three knob tetrapeptide 
sequences, namely GPRP (SEQ ID NO: 1 ), GPRV (SEQ ID 
40 N0:2) and GHRP (SEQ ID N0:3), was modified using site-
directed mutagenesis (FIG. 2). The coding sequence for the 
model protein, the 20 kDa FnIII9_10 fragment, was then 
inserted using standard molecular cloning techniques. The 
model protein has a known crystal structure, can be produced 
45 using standard bacterial expression systems, and may be 
detected via immunological assays using a number of com-
mercially available antibodies (Petrie TA, et al. Biomaterials 
2006, 27(31):5459-5470; Martino MM, et al. Biomaterials 
2009, 30(6):1089-1097; Leahy DJ, et al. Cell 1996, 84(1): 
155-164). The GST tag served dual purposes as affinity tag 
50 
and a measure ofthrombin cleavage efficacy. Using this plat-
form cloning and expression system the following knob-pro-
tein fusions were successfully expressed and purified: GSPE-
FnIII9_10 (non-binding control, SEQ ID NO: 11 ), GPRP-
FnIII9_10 (SEQ ID NO:l), GPRV-FnIII9_10 (SEQ ID N0:2) 
55 and GHRP-FnIII9_10 (SEQ ID N0:3). 
Example 2 
Plasmids containing the FnIII9_10 insert were transformed 60 
into electro-competent BL21 E. coli and protein production 
Evaluating Fusion Protein Fibrinogen-Binding 
Affinity Using SPR 
of the Glutathione S-transferase (GST)-tagged proteins 
stimulated as recommended by the manufacturer. Following 
appropriate culture, cells were pelleted by centrifugation at 4 ° 
C. and resuspended in ice-cold PBS supplemented with pro- 65 
tease inhibitor (Roche, Indianapolis, Ind.), then lysed by add-
ing 1 mg/mL oflysozyme followed by sonication. 1 % Triton 
Materials and Methods 
Preparation of Fibrinogen Fragment D 
Human fibrinogen (# FIB3, Enzyme Research Laborato-
ries, South Bend, Ind.) at 2 mg/mL was digested with 0.1 
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37 
U/mL human plasmin (Enzyme Research Laboratories) in 
HEPES+Ca buffer (150 mM NaCl, 5 mM CaC12, 25 mM 
HEPES, pH 7.4) overnight at room temperature. Fragment D 
(or D-domain) was isolated as previously described, with 
slight modifications, using a polymeric resin with covalently 5 
linked GPRPAA (SEQ ID NO: 10) peptide (Kostelansky MS, 
et al. Biochemistry 2002, 41(40):12124-12132). Briefly, the 
plasmin-digested fibrinogen and GPRPAA-beads were incu-
bated for 30 min, with occasional agitation. The unbound 
protein fragments were removed with exhaustive washing 10 
with HEPES+Ca buffer. Fragment D was eluted using 1 M 
sodium bromide, 50 mM sodium acetate, pH 5.3 and 
exchanged back into HEPES+Ca buffer using a centrifugal 
filter with MWCO 10,000. 
38 
FnIII9_10 (SEQ ID N0:2) generated a Kn of 125±6 µM while 
both GHRP-FnIII9_10 (SEQ ID N0:3) and the control GSPE-
FnIII9_10 (SEQ ID NO: 11) demonstrated no detectable bind-
ing to fragment D. Additionally, the specificity of the GPRP-
FnIII9_10 (SEQ ID NO:l) interaction with the pocket was 
demonstrated by adding a 10-molar excess of soluble GPRP 
(SEQ ID NO:l) peptide to the flow analyte solution (FIG. 
3B). A significant increase in Kn was observed from 3.0 µM 
to 43±4 µM under these competing conditions, suggesting 
that that the fibrin( ogen)-binding capacities of GPRP-
FnIII9_10 (SEQ ID NO:l) is attributed to its N-terminal knob 
sequence. Based on the promising SPR data, further investi-
gations were focused on the high affinity GPRP-FnIII9_10 
(SEQ ID NO:l) protein and the non-binding control GSPE-
15 FnIII9_10 (SEQ ID NO: 11 ). 
Surface Plasmon Resonance (SPR) Binding Assays 
Example 3 
The BIACORE® 2000 was used to perform SPR experi-
ments to determine the equilibrium dissociation constants 
(Kn) of the various Gxxx-FnIII9_10 (SEQ ID N0:20) proteins 20 
to fibrinogen fragment D covalently immobilized to gold-
coated coverslips via self-assembled monolayer (SAM) sur-
face chemistry. Mixed SAMs were generated on gold-coated 
chips as described previously by incubating with a 1 mM 
mixture of tri( ethylene glycol)-terminated alkanethiol (HS- 25 
(CH2)11-(0CH2CH2)3---0H; EG3 ) andcarboxylic acid-ter-
minated alkanethiol (HS-(CH2)11-(0CH2CH2)6-
0CH2COOH; EG6-COOH) thiols for 4 h (Petrie TA, et al. 
Biomaterials 2006, 27(31):5459-5470). After mounting the 
gold chip in the BIACORE® 2000, the EG6-COOH compo- 30 
nent of the SAM was activated with 200 mM EDC and 50 mM 
Evaluating Fusion Protein Fibrinogen-Binding 
Affinity Using ELISA 
Materials and Methods 
ELISA Binding Assays 
A modified ELISA technique was used to establish the 
affinity of fibrinogen for the various Gxxx-FnIII9_10-C (SEQ 
ID N0:20) proteins covalently immobilized on maleimide-
activated plates via their C-terminal cysteines. Sulfhydryl-
containing proteins/peptides were added to pre-blocked 
maleimide-activated 96-well plates (Pierce, Thermo Scien-
NHS in 0.1 M 2-(N-morpho )-ethanesulfonic acid and 0.5 M 
NaCl, pH 6.0 (5.4/min for 10 min). Fragment D was then 
immobilized via NHS-amine linkages (5 µUmin for 10 min). 
Unreacted NHS groups were quenched with 20 mM ethano-
lamine (10 µUmin). Upon stabilization of the baseline signal, 
varying concentrations of the Gxxx-FnIII9_10 (SEQ ID 
N0:20) were flowed at 25 µUmin for 4 min immediately 
followed by a 10 min dissociation phase; the fragment D 
surface was regenerated between analyte runs. All sensor-
gram response curves were normalized to a reference flow 
cell in which fragment D was not immobilized. SPR sensor-
grams were analyzed and equilibrium constants were deter-
mined with Scrubber 2 and ClampXP software (Center for 
Biomolecular Interactions Analysis, University of Utah) 
(Morton TA, et al. Anal Biochem 1995, 227(1): 176-185). 
Results 
tific, Rockford, Ill.) at 10 µg/mL in conjugation buffer (CB) 
comprising 150 mM NaCl, 100 mM phosphate, 10 mM 
EDTA, pH 7 .2, with attachment occurring via maleimide-
35 sulfhydryl (thioether) linkages. TCEP (1 mM) was added to 
maintain sulfhydryl groups in the reduced form. Following, 
unreacted maleimide groups were quenched with 20 µg/mL 
cysteine in CB. Human fibrinogen (25 µg/mL) was incubated 
with the substrates and unbound protein removed by washing. 
40 Bound fibrinogen was detected using HRP-conjugated goat 
anti-fibrinogen antibody (MP Biomedicals #55239) and 
I-Step TM Ultra TMB-ELISA (Pierce). The TMB reaction was 
quenched with 1 M H2S04 before measuring the Abs450 nm 
using the SPECTRAMAX® M2 (Molecular Devices, Sunny-
45 vale, Calif.). All intervening wash steps were conducted using 
washing buffer (WB) comprising 150 mM NaCl, 100 mM 
phosphate, 0.05% Tween-20, pH 7.2; all binding steps were 
conducted using binding buffer (BB) comprising PBS+ 1 % 
BSA. For basic affinity assays, the concentration of the fusion 
The affinity of Gxxx-FnIII9_10 (SEQ ID N0:20) proteins 
for immobilized fibrinogen fragment D was examined using 
surface plasmon resonance (SPR). Fibrinogen fragment D, 
comprising the C-terminal polymerization pockets of fibrino-
gen (i.e. D-domain) without the N-terminal knobs, was 
covalently immobilized on gold chips via self-assembled 
monolayers (SAMs). Following, solutions ofGxxx-FnIII9_10 
(the analyte, SEQ ID N0:20) were flowed across the frag- 55 
ment D surface, with protein-protein interactions registering 
50 proteins was varied. For specificity assays, varying concen-
trations of Gxxx (SEQ ID N0:20) tetrapeptides (Genscript, 
Piscataway, N.J.) were added to the fibrinogen solution dur-
ing incubation with the covalently immobilized proteins. 
Results 
In addition to the Gxxx-FnIII9_10 (SEQ ID N0:20) recom-
binant proteins described above, equivalent versions with an 
additional C-terminal cysteine were expressed and purified. 
The Gxxx-FnIII9_10-C (SEQ ID N0:20) proteins were immo-
bilized on maleimide-activated 96-well plates via maleimide-
as an increase in response units, as measured using the Bia-
core 2000 system (FIG. 3A). For each protein, the equilib-
rium response at each concentration was plotted against con-
centration and fit to a single-site binding model to determine 
the equilibrium dissociation constant, Kn (FIG. 3B). GPRP-
FnIII9_10 (SEQ ID NO: 1) had the greatest affinity for immo-
bilized fibrinogen fragment D, with a Kn of3.0±0.1 µM. This 
is congruent with recently presented SPR data reporting Kns 
for knob-containing N-terminal disulphide knot (NDSK) 
fragments in similar µM range (Geer C B, et al. J Thromb 
Haemost 2007, 5(12):2344-2351). In contrast, GPRV-
60 sulfhydryl chemistry, allowing the unidirectional presenta-
tion of their N-terminal knobs to fibrinogen-containing 
solutions in the wells. Using standard ELISA techniques, the 
bound fibrinogen was detected using an anti-fibrinogen HRP-
conjugate, with stronger signals corresponding to increased 
65 amounts of bound fibrinogen. Complementing the SPR data, 
the ELISA results indicate that soluble fibrinogen bound to 
immobilized GPRP-FnIII9_10-C (SEQ ID NO:l) but not the 
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control, GSPE-Fn!II9_10-C (SEQ ID NO: 11) (FIG. 4A). This 
demonstrates the mechanism of action, that fibrinogen is 
binding the knob-protein fusion via the knob sequences and 
not via interaction with the fibronectin domains in our model 
protein. 
40 
turbidity were taken every minute for 1 h. To determine the 
amount of unclotted protein, the clots were spun down and the 
supernatant or clot liquor was analyzed for total protein using 
the Quant-iT protein assay (Invitrogen, Carlsbad, Calif.). 
Rheological Assays 
The Bohlin CVO 120 high resolution rheometer (Malvern 
10 Instruments, Westborough, Mass.) with plate-plate geometry 
To further demonstrate specificity, soluble tetrapeptides 
modeled after fibrin knob sequences were added in large 
molar excess (102 - to 104 -fold) to the fibrinogen solution that 
was to be incubated with immobilized GPRP-FnIII9_10-C 
(SEQ ID NO:l). As expected, free GPRP (SEQ ID NO:l) 
tetrapeptides competed with the immobilized GPRP-
FnIII9_10-C (SEQ ID NO: 1) for binding to fibrinogen, result-
ing in a dose-dependent inhibition offibrinogen binding fol-
lowing a one-hour pre-incubation (FIG. 4B). This result sug- 15 
gests that the GPRP (SEQ ID NO: 1) sequence is the mediator 
was used to assess the viscoelastic characteristics of fibrin 
clots at room temperature. Briefly, fibrinogen (preincubated 
with or without Gxxx-FnIII9_10-biotin (SEQ ID N0:20) as 
indicated) and enzyme mixtures with identical compositions 
as those used in the turbidity and clottability assays were 
mixed by pipetting and immediately added to the bottom 
plate. The upper plate (14 mm diameter) was immediately 
of the interaction between the immobilized protein and 
fibrinogen. The tetrapeptides GPRV (SEQ ID N0:2) and 
GHRP (SEQ ID N0:3) are also known to bind fibrinogen via 
knob:pocket interactions, albeit with reduced affinities 
(Laudano AP, et al. Biochemistry 1980, 19(5):1013-1019). 
These results indicate that GPRV (SEQ ID N0:2) competed 
with GPRP-FnIII9_10 (SEQ ID NO: 1) for binding to fibrino-
gen, but to a lesser extent as compared to GPRP (SEQ ID 
NO:l), while GHRP (SEQ ID N0:3) was not a significant 25 
competitor to GPRP-Fn!II9_10 (SEQ ID N0:19) under the 
experimental conditions. Notably, these results agree with the 
SPR data indicating thatthe affinity constant ofGPRV-FnIII9_ 
lowered to a gap size of 1 mm and the mixture was allowed to 
20 
polymerize for 30 min in a humid chamber. Following, oscil-
lating measurements were taken over a frequency range of 
0.05 to 1.0 Hz at a constant strain of 0.5%. 
Results 
Since knob:pocket interactions are involved in fibrin 
assembly, the addition of non-native knob-protein fusions 
could potentially interfere with this process and impede 
matrix formation, thereby limiting the utility of this affinity 10 (SEQ ID N0:2) was at least an order of magnitude smaller 
than that of GPRP-FnIII9_10 (SEQ ID NO: 19), while GHRP- 30 
FnIII9_10 (SEQ ID N0:3) had little affinity for fibrinogen 
fragment D. These results support the interpretation that the 
interaction between the GPRP-FnIII9_10 (SEQ ID NO: 1) pro-
tein and fibrinogen is primarily mediated by the respective 35 
N-terminal tetrapeptide sequences through specific interac-
tions with fibrin( ogen) pockets. 
system for the retention of proteins within fibrin matrices. 
The impact of such knob-protein fusions on fibrin assembly 
was therefore evaluated. GPRP-FnIII9_10-C (SEQ ID NO:l) 
was selectively conjugated to maleimide-functionalized 
biotin, generating GPRP-FnIII9_10-biotin (SEQ ID NO:l) 
conjugates that can be quantitated via sandwich ELISA. 
GPRP-Fn!II9_10-biotin (SEQ ID NO: 1) proteins were prein-
cubated with fibrinogen before clotting was induced by the 
addition of factor XIIIa and either thrombin (exposes bothA-
and B-knobs) or batroxobin (exposes the A-knobs). The pro-Example 4 
Fibrin Assembly in the Presence of Fusion Protein 
Materials and Methods 
Biotinylation of Fusion Proteins 
Gxxx-FnIII9_10-C (SEQ ID N0:20) proteins were conju-
gated via the sulfhydryl group of the C-terminal cysteine to 
maleimide-functionalized biotin (maleimide-PEG2 -biotin; 
Pierce #21902) following the manufacturer's recommended 
protocol. Unreacted maleimide-PEG2 -biotin was removed 
using Slide-A-Lyzer dialysis cassettes with MWCO 3,500 
(Pierce). The extent ofbiotinylation was determined using the 
Pierce Biotin Quantitation Kit (Pierce). 
Fibrin Clotting Assays 
Clotting was initiated in a 96-well plate format and the 
Abs350 nm used as a standard measure of turbidity. Briefly, 
increasing doses of the Gxxx-FnIII9_10-biotin (SEQ ID 
N0:20) proteins were preincubated with 4 mg/mL human 
fibrinogen (ERL# FIB3) in Tris+Ca buffer (140 mM NaCl, 5 
mM CaC12 , 20 mM Tris, pH 7.4). Following the 1 h preincu-
bation, clotting was initiated by adding 1 U/mL of human 
thrombin (ERL) or batroxobin moojeni (Centerchem, Nor-
walk, Conn.), and 1 U/mL factor XIIIa (kindly donated by 
Baxter AG, Vienna Austria). Real time measurements of clot 
40 cess of fibrin assembly can be inferred from the gross absor-
bance of the fibrinogen-containing mixture since the lateral 
aggregation of protofibrils during clotting results in a rapid 
rise in turbidity (Weisel J W, et al. Biophys 1992, 63(1):111-
45 128). The turbidity curves obtained suggest that fibrin assem-
bly in the presence ofthrombin (FIG. SA) or batroxobin (FIG. 
SB) was not significantly impacted by the presence ofGPRP-
FnlII9_10-biotin (SEQ ID NO:l), or the control GSPE-
Fn!II9_10-biotin (SEQ ID NO: 11 ), at the conjugate:fibrinogen 
50 molar ratio of 1:10. Rheological assaying of clots formed 
following a 30-minute clotting time suggests that the pres-
ence of either conjugate did not significantly affect the native 
viscoelastic properties of the clots (FIG. SC). Moreover, 
quantitation of the soluble proteins in the clot liquor (the 
55 remaining supernatant after spinning down the insoluble 
fibrin) also indicates that the presence of GPRP-FnIII9_10-
biotin (SEQ ID NO: 1 ), or the control GSPE-FnIII9_10-biotin 
(SEQ ID NO: 11 ), did not significantly impact the clottability 
of the mixture (FIG. SD). These results agree with past 
60 research showing that at least a 100-fold excess of the GPRP 
(SEQ ID NO:l) tetrapeptide was necessary to completely 
inhibit fibrin assembly (Laudano AP, et al. Proc Natl Acad Sci 
USA 1978, 75(7):3085-3089) and suggest that the presence 
of knob-protein fusions will not significantly interfere with 
65 the formation of the fibrin matrix when present at the nano-
gram concentrations relevant for use in protein delivery sys-
tems for growth factors. 
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Example 5 
Evaluating Fusion Protein Retention in Fibrin 
Matrices Using Release Assays 
Materials and Methods 
Protein Release Assays 
Analogous to the clotting assays, Gxxx-FnIII9_10-biotin 
10 
(SEQ ID N0:20) was preincubated with fibrinogen in Tris+ 
Ca buffer in 2 mL conical bottom tubes. Clotting was initiated 
by adding thrombin or batroxobin, and factor XIIIa. After a 
one-hour incubation, the resulting clot was overlaid with 1 15 
mL Tris+Ca buffer. The entire volume of buffer was removed 
and replaced with fresh buffer at 1, 4, 8, 12, 24, 48, 72, 
96-hour timepoints for analysis. Gxxx-FnIII9_10-biotin (SEQ 
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released within the first 24 hours as compared to GSPE-
FnIII9_10-biotin (SEQ ID NO: 11) for both the thrombin 
(FIGS. 6A,B) and batroxobin (FIGS. 6C,D) clots, suggesting 
that the affinity between GPRP-FnIII9_10-biotin (SEQ ID 
NO:l) and fibrin(ogen) was able to retard the initial 'burst 
release' of protein from the fibrin matrix, resulting in an 
overall greater retention of the loaded protein within the clot. 
Nonetheless, statistical comparisons of the absolute quantity 
of protein released at each time point did not reveal major 
differences between GPRP-FnIII9_10-biotin (SEQ ID NO:l) 
and GSPE-FnIII9_10-biotin (SEQ ID NO: 11) conjugates with 
respect to the amount of protein released, particularly after 
the initial 24-hour burst release. Rather, statistically signifi-
cant differences were found between the amounts of protein 
released from thrombin-versus batroxo bin-catalyzed clots for 
both GPRP-FnIII9_10 (SEQ ID NO:l) (FIG. 7A, B) and 
GSPE-FnIII9_10 (SEQ ID NO:ll) (FIG. 7C, D), suggesting 
20 that other factors may be involved in mediating protein reten-
tion past the 24-hour time point. 
ID N0:20) proteins in the removed supernatant samples were 
quantitated using a sandwich ELISA. Briefly, 96-well ELISA 
plates were coated with 5 µg/mL streptavidin, then washed 
and blocked with 1 % BSA. The sample, mouse monoclonal 
anti-FnIII9_10 antibody (HFN7.1; Developmental Studies 
Hybridoma Bank, Iowa City, Iowa) and HRP-conjugated goat 25 
anti-mouse antibody (Pierce #1858413) were added sequen-
tially to the plate with intervening wash steps. TMB was 
added to react with the HRP and the reaction quenched with 
H2 S04 before measuring the Abs450 nm· 
Results 
30 
GPRP-FnIII9_10-biotin (SEQ ID NO: 1) binds fibrin( ogen) 
pockets and does not interfere with the clotting process at the 
loading concentrations desired for targeted application. The 
retention of GPRP-FnIII9_10-biotin (SEQ ID NO: 1) con ju- 35 
gates within three-dimensional fibrin matrices was therefore 
examined by monitoring protein release from the clots into 
the surrounding buffer reservoir. In particular, the release 
profiles from both normal thrombin-catalyzed clots and 
40 batroxobin-catalyzed clots were evaluated; batroxobin selec-
tively exposes the A-knobs but not the B-knobs, theoretically 
leaving an excess of binding pockets that should improve 
retention characteristics. As described in the previous section, 
the GPRP-FnIII9_10-biotin (SEQ ID NO:l) conjugates were 45 
preincubated with fibrinogen at a 1: 10 molar ratio (conjugate: 
fibrinogen), before clotting was induced by the addition of 
factor Ma and eitherthrombin or batroxobin. After a one-hour 
incubation period, the clot was overlaid with pre-warmed 
buffer and incubated at 37° C. with agitation. Samples taken 
at regular intervals were evaluated for the presence of fibrin 
50 
( ogen) and conjugate via sandwich ELISAs. In particular, the 
HFN7 .1 conformation-specific antibody was used against the 
conjugates to further demonstrate that the conformational 55 
integrity of the FnIII9_10 was preserved during the release 
assay. Additionally, GPRP-FnIII9_10-biotin (SEQ ID NO: 1) is 
capable of binding to ELISA plates coated with fibrinogen 
and being detected by the same antibody (data not shown), 
indicating that the conformational integrity of the FnIII9_10 
60 
domain is preserved even while bound to fibrin(ogen). 
The amount of soluble fibrin( ogen) in all the samples 
remained below the detection limit (-10 ng/mL) of the fibrin 
( ogen) ELISA, indicating that the clots remained intact dur- 65 
ing the four-day incubation period. In the FnIII9_10-biotin 
ELISA, less GPRP-FnIII9_10-biotin (SEQ ID NO:l) was 
Example 6 
Evaluating Fusion Protein Retention in Fibrin 
Matrices Using Perfusion Assays 
Materials and Methods 
Perfusion Assays with Confocal Microscopy 
To examine the retention of knob fusion proteins within 
fibrin polymer matrices, microfluidic techniques were 
coupled with confocal microscopy. Microfluidic chamber 
templates (Y-shaped: 4 cm length, 1 mm width, 60-75 µm 
height) were fabricated with standard photolithography tech-
niques on silicon wafers. Polydimethylsiloxane (PDMS; Syl-
gard 184; Dow Corning, Midland, Mich.) was cast onto the 
silicon wafer template, cured, and removed from the wafer to 
obtain the microfluidic chambers. Individual PDMS devices 
were mounted onto clean coverslips immediately after receiv-
ing plasma treatment (negative polarization for 1 min at 25 
mAnlp ). Fibrinogen was covalently immobilized to the inte-
rior surface of the PDMS channels to promote uniform fibrin 
matrix formation on all chamber wall surfaces, thereby pre-
venting the separation between the chamber surface and fibrin 
matrix during perfusion. Briefly, the device channels were 
treated with 1.5% 3-methacryloxypropyltrimethoxysilane in 
methanol (20 min), then 0.5% gluteraldehyde (30 min), and 
then incubated with fibrinogen (100 µg/ml; 30 min). After 
subsequent rinsing with Tris buffer, a 2 mg/mL fibrinogen 
solution containing 10% labeled fibrinogen (Alexa Fluor-
555; Invitrogen), 1 U/mL thrombin, 1 U/mL factor XIIIa, and 
labeled Gxxx-FnIII9_10 (SEQ ID N0:20) (Alexa Fluor-633; 
Invitrogen) in a 1: 10 molar ratio (Gxxx-FnIII9_10:fibrinogen) 
was injected into the chamber and allowed to polymerize for 
1 h. Following polymerization, Tris+Ca buffer was perfused 
through the chamber at 10 µUmin for 30 min. Confocal 
z-stack micrographs (2 µm thick stack with 0.5 µm intervals; 
Zeiss LSM 510) were taken before the Tris+Ca buffer rinse 
and then every 5 min after commencement of perfusion. 
Throughout the duration of the experiment and across sample 
groups, the image acquisition settings remained constant (i.e. 
pinhole, master gain) for both fluorophores. Colocalization 
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and release of the Gxxx-FnIII9_10 (SEQ ID N0:20)was evalu-
ated and quantitated with confocal software ZEN (Carl Zeiss 
International). Using the colocalization analysis tool in ZEN, 
baseline thresholds for both fibrin and Gxxx-FnIII9_10 (SEQ 
44 
ID N0:20) signal intensity were held constant for each set of 
images. Calculated parameters included the relative area of 
colocalization (colocalized area relative to total area), mean 
signal intensity for each channel above the threshold, colo-
calization coefficients for each fluorescent channel (total 10 
number of co localized pixels relative to total number of pixels 
above the threshold for a given channel; O=no co-localization 
and 1 =all pixels co localized), and Pearson's correlation coef-
was labeled via NHS-amine chemistry with carboxylic acid 
terminated Alexa Fluor-555. Similar to the release assays, 
GPRP-FnIII9_10-AF633 (SEQ ID NO:l) or GSPE-FnIII9_10-
AF633 (SEQ ID NO: 11) was pre-incubated with fibrinogen at 
1:10 molar ratio (conjugate:fibrinogen) for 1 h prior to initi-
ating clot, formation with thrombin and factor XIIIa within a 
microfluidic channel. Confocal images were taken following 
polymerization (prior to perfusion) and then every five min-
utes following the initiation of buffer perfusion at a rate of 10 
µUmin. According to the confocal micrographs, the GPRP-
FnIII9_10-AF633 (SEQ ID NO: 1) conjugates were incorpo-
rated into the fibrin matrix and were retained with in the clots ficient (R; 1 =high correlation; <O=no correlation). 
Statistics 
All experimental data are reported as mean±SEM of at 
least 3 independent triplicate experiments. Results were ana-
lyzed using GraphPad PRISM 5.0. Statistical comparisons 
for all experimental sets were based on one-way ANOVA 
using the Tukey post-hoc test for pair-wise comparisons with 
significance defined by p<0.05. 
Results 
A perfusion system was designed to visually examine the 
real-time dynamics of protein retention within three-dimen-
sional fibrin matrices using confocal microscopy. GPRP-
FnIII9_10-C (SEQ ID NO: 1) (and the control GSPE-FnIII9_10-
C, SEQ ID NO: 11) was fluorescently labeled by conjugation 
to maleimide-activated Alexa Fluor-633; while fibrinogen 
15 under significant perfusion and slowly released over a span of 
30 min at a buffer flow rate of 10 µUmin. Meanwhile GSPE-
FnIII9_10-AF633 (SEQ ID NO: 11) displayed minimal to no 
fluorescent signal associated with fibrin fibers at any time-
point. Colocalization analysis for each set of confocal micro-
20 graphs further demonstrated that 94.2% of fibrin matrix was 
initially colocalized with GPRP-FnIII9_10 (SEQ ID NO:l) 
(Table 1), whereas in the negative control only 0.6% fibrin 
colocalized with GSPE-FnIII9_10 (SEQ ID NO:l 1) (Table 2). 
25 These results indicate that the GPRP-FnIII9_10 (SEQ ID 
NO:l) fusion protein, but not GSPE-FnIII9_10 (SEQ ID 
NO: 11) was incorporated into the fibrin network. Moreover, 
12.8% of the fibrin matrix still retainedGPRP-FnIII9_10 (SEQ 
ID NO: 1) after undergoing a rigorous perfusion of buffer 
30 demonstrating a robust interaction between the fusion protein 
and fibrin. 
TABLE 1 
Incorporation and retention of GPRP- FnIIl9_10 
Time Mean Intensity Relative Area of Co localization Coefficient Correlation 
(min) Fibrin GPRP-Fn Colocalization Fibrin GPRP-Fn Coeffcient (R) 
0 100 ± 33 100 ± 33 94.2% 0.981 0.965 0.47 
10 105 ± 22 55 ± 14 28.5% 0.325 0.956 0.19 
20 105 ± 22 52 ± 13 19.1% 0.219 0.948 0.14 
30 99 ± 19 51±12 12.8% 0.159 0.926 0.11 
TABLE2 
Limited incorporation ofGSPE- FnIIl9 _10 in fibrin clots 
Time Mean Intensity Relative Area of Co localization Coefficient Correlation 
(min) Fibrin GSPE-Fn Colocalization 
0 100 ± 39 46 ± 6 0.6% 
10 85 ±23 45 ±5 0% 
20 98 ± 44 44 ± 5 0.1 % 
30 90±38 38±6 0.1% 
Fibrin 
0.01 
0.001 
0.003 
0.003 
GSPE-Fn Coeffcient (R) 
0.739 0.04 
0.521 -0.06 
.0413 0.02 
0.377 -0.02 
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Example 7 
Kinetic Binding Models 
Materials and Methods 
Fibrin Knob 'A' Peptides 
Peptide sequences included GPRVV AAC (SEQ ID NO: 8), 
GPRVVERC (SEQ ID N0:7), GPRPAAC (SEQ ID N0:4), 
GPRPPERC (SEQ ID N0:6), GPRPFPAC (SEQ ID N0:5), 
and GPSPAAC (SEQ ID N0:9) (GenScript, Inc, Piscataway, 
N.J.; Table 3). The peptide sequences were designed with a 
carboxyl-terminal cysteine residue to permit sulfhydryl-tar-
geted reactions for future conjugation chemistries. 
TABLE3 
Experimental knob 'A' peptides and corresponding properties 
Peptide 
Sequence Property 
GPRVVERC Mimics native sequence through 7th 
residue 
GPRVV.AA.C Mimics native sequence minus 
additional charged residues 
GPRPAAC Stabilized backbone 
GPRPFPAC 
GPRPPERC 
GPSPAAC 
Stabilized backbone 
Stabilized backbone additional 
charged residues 
Negative control 
Known dysfibinrogen mutant 
Net SEQID 
Charge NO 
+1 7 
+1 
+1 4 
+1 
+1 
0 9 
Preparation of Fibrinogen Fragment D 
Human fibrinogen (Enzyme Research Laboratories, South 
Bend, Ind.) at 2 mg/mL was digested with O.I U/mL human 
plasmin (ERL) in HEPES+CaC12 buffer (I50 mM NaCl, 5 
mM CaC12, 25 mM HEPES; pH 7.4) overnight at room tem-
perature. Fragment D was isolated as previously described, 
with slight modifications (Kostelansky MS, et al. Biochem-
istry. 2002; 4I(40):I2I24-I2I32). Briefly, the plasmin-di-
gested fibrinogen and GPRPAA (SEQ ID NO: IO) beads were 
incubated for 30 min, with occasional agitation. The unbound 
proteins and protein fragments were removed with excessive 
washing with HEPES+CaC12 buffer. Fragment D was eluted 
with IM sodium bromide and 50 mM sodium acetate (pH 
5.3). Eluted samples were pooled together and exchanged 
back into HEPES+CaC12 buffer using a centrifugal filter 
(MWCO I0,000). Fragment D was verified by SDS-PAGE 
and stored at -80° C. until use. 
Binding Kinetics with Surface Plasmon Resonance 
(SPR) 
The Biacore 2000 (Biacore Lifesciences, GE Healthcare, 
Pittsburgh, Pa.) was used investigate kinetic binding con-
stants (ka and kd) of knob 'A' peptide variants for fibrinogen 
fragment D. Briefly, fragment D was covalently immobilized 
to gold-coated SPR sensor chips via self-assembled mono-
layer (SAM) surface chemistry in order to generate a non-
fouling surface with a controlled density of reactive carboxy-
lic acid groups. Mixed SAMs were generated on gold-coated 
chips as described previously (Petrie TA, et al. Biomaterials. 
2006; 27(3I):5459-5470) by incubating with a I mMmixture 
of tri( ethylene glycol)-terminated alkanethiols 
(HS-(CH2)11-(0CH2CH2)3-0H; EG3 ; ProChimia, 
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Poland) and carboxylic acid-terminated alkanethiols (HS-
(CH2)11-(0CH2CH2)6-0CH2COOH; EG6-COOH) for 4 
hrs. Upon loading the sensor chip into the Biacore 2000, the 
EGcCOOH in all four flow cells was activated by flowing 
5 200 mM I-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDC; Sigma Aldrich, St. Louis, Mo.) and 50 mM N-hydrox-
ysuccinimide (NHS; Sigma Aldrich) (5 µUmin for I 0 min). 
Immediately following activation, fragment D was immobi-
lized in three flow cells (5 µUmin for IO min) to achieve 
10 I 800-2000 resonance units (RU; IRU-I pg/mm2). Unreacted 
NHS groups were quenched in all four flow cells (three 
sample cells and one reference cell) with 20 mM ethanola-
mine (I 04/min for I 0 min). Upon stabilization of the baseline 
signal, kinetic binding experiments were run in duplicate with 
15 the peptide variants as the flow analytes. Five varying con-
centrations for each peptide (0.94 µM to I 50 µM) were flowed 
at 25 µUmin for 4 min immediately followed by a I 0 min 
dissociation phase. Between each run, the surface was regen-
erated with IM sodium bromide and 50 mM sodium acetate 
20 (pH 6.0). SPR experiments were performed three times with 
varying peptide injection order to rule out binding trends 
associated with injection sequence. Peptide solutions were 
incubated with tris(2-carboxyethyl)phosphine (TCEP) 
immobilized on agarose beads (Thermo Fisher Scientific, 
25 Inc; Rockland, Ill.) to ensure reduction of any disulfide bonds 
between C-terminal cysteines. Mass spectrometry analysis 
(Fast Atom Bombardment) of peptide solutions demonstrated 
that the peptides did not dimerize over the course of the SPR 
experiment. 
30 Results 
To investigate the dynamic binding profile between the 
fibrinogen/fibrin holes and knob peptide variants, SPR was 
employed. Binding interactions were evaluated by flowing 
the knob peptides over an immobilized surface of fragment D 
35 (FIG. 8). By immobilizing fragment D as opposed to full-
length fibrinogen, the kinetic binding model was simplified to 
a heterogeneous 2-site ligand model (i.e. one hole 'a' and hole 
'b' per ligand) as opposed to a 4-site model (i.e. two of each 
hole 'a' and hole 'b'per ligand). The data was modeled using 
40 both a Langmuir I: I model and a heterogeneous ligand model 
to compare previously established binding affinities to a more 
dynamic two-site model. However, the complexity of the 
heterogeneous model fitted parameters for sites I and 2 (i.e. 
maximal binding response, ka, and kd) limits direct designa-
45 tion or assignment of holes 'a' or 'b' to site I or 2. An 
additional mass transport limited model was tested as well, 
but did not fit the experimental data for any of the peptides. All 
peptide SPR data was fit except for the negative control pep-
tide, GPSPAAC (SEQ ID N0:9), where minimal binding 
50 response was observed. 
In comparing model simulation results, the heterogeneous 
ligand model fit the experimental binding data far better than 
the Langmuir I: I model. Response, simulation curves, and 
residual plots are presented in FIGS. 9, 11 and 12. Looking 
55 specifically at the RSS, the range for the I: I Langmuir model 
(I .497 to 2.I97; Table 4) was higher than the heterogeneous 
ligand model (0.9437 to 1.474; Table 5), suggesting that the 
fitted heterogeneous ligand model deviated less from the 
experimental data. Additionally, graphically plotting the 
60 residuals over time revealed that the residuals for I: I Lang-
muir model followed a systematic trend (FIG. 9C), indicative 
of fitting an inappropriate model to the experimental data 
(Cornish-BowdenA. Methods. 200I; 24(2):I8I-I90). Incon-
trast, the residuals for the heterogeneous model were lower 
65 and more randomly distributed (FIG. 9D), indicating that this 
model adequately describes the binding response curves 
(Morton TA, et al. Methods Enzymol. I998; 295:268-294; 
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Comish-Bowden A. Methods. 2001; 24(2):181-190). Based 
on these analyses and observations, further comparisons of 
binding parameters were performed with the results from the 
heterogeneous ligand model. 
TABLE4 
Langmuir 1: 1 model - Fitted parameters. 
Parameter GPRPAAC GPRPFPAC GPRPPERC GPRVVERC 
Bm= 21.47 ± 0.19 17.74 ± 0.08 19.20 ± 0.21 16.27 ± 0.08 
(RU) 
48 
mJections from each reference-subtracted response curve 
(Myszka D G. Mo!. Recognit. 1999; 12(5):279-284). All 
double-referenced curves were normalized by the molecular 
weight of each peptide and multiplied by 1000 to account for 
GPRVVAAC 
18.88 ±0.18 
ka (M-ls-1) X 1.14 ± 0.03 12.5 ± 0.26 1.29 ± 0.03 0.28 ± 0.004 0.09 ± 0.001 
10-3 
kd (s-1) x 11.71 ± 0.17 7.27 ± 0.08 9.92 ± 0.13 
103 
RSS 2.197 2.092 1.885 
SEQ ID 4 
NO: 
Bmax =maximal binding capacity of fragment D (resonance units; RU) 
ka =association rate 
kd =dissociation rate 
RSS =residual sum of squares 
TABLES 
23.43 ± 0.23 
1.521 
7 
Heterogeneous ligand model - Fitted parameters 
Parameter GPRPAAC GPRPFPAC GPRPPERC 
SEQ ID NO: 4 
Bm= 19.38 ± 0.23 17.59 ± 0.13 14.58 ± 0.23 
(RU) 
kal (M-ls-1) X 2.84 ± 0.14 21.72 ±0.73 3.22 ± 0.12 
10-3 
kd1 (s-1) x 12.83 ± 0.49 81.10 ± 2.23 58.73 ± 1.86 
103 
Km 4.53 3.73 18.23 
(µM)** 
B*max 5.91 ± 0.08 11.34 ± 0.08 5.92 ± 0.13 
(RU) 
ka2 (M-ls-1) X 1.05 ± 0.09 1.81 ± 0.04 1.01±0.03 
10-3 
kd2 (s- 1) x 8.95 ± 1.05 1.96 ± 0.04 2.96 ± 0.09 
103 
KD2 8.52 1.08 2.93 
(µM)** 
RSS 1.474 0.9887 0.9437 
Bmax =maximal binding capacity of fragment D (resonance units; RU) 
ka =association rate 
kd =dissociation rate, RSS =residual sum of squares 
**denotes calculated Kn from fitted ka and lCJvalues where Kn= kllCa 
Example 8 
GPRVVERC 
7 
25.61 ± 0.28 
1.07 ± 0.03 
57.67 ± 2.24 
53.89 
10.33 ± 0.23 
0.26 ± 0.01 
4.07 ± 0.06 
15.71 
0.9817 
10.73 ± 0.04 
1.497 
GPRVVAAC 
8.36 ± 0.24 
0.62 ± 0.04 
30.08 ± 1.51 
48.51 
13.52 ± 0.32 
0.04 ± 0.001 
1.00 ± 0.07 
25.00 
1.266 
minor variations in response due to molecular weight. The 
resulting curves were then analyzed and fitted to the kinetic 
Fitted Binding Affinity Parameters 
Materials and Methods 
50 
models. Kinetic modeling and simulations were performed 
with ClampXP software using the Langmuir 1: 1 model or the 
heterogeneous ligand model; globally fitted parameters were 
determined for each kinetic data set per peptide. Equilibrium 
SPR Analysis and Evaluation 55 binding constants were calculated from fitted kinetic con-
stants. Goodness of fit for each model was determined by 
evaluating the residual plots and residual sum of squares 
(RSS) (Myszka D G. J Mo!. Recognit. 1999; 12(5):279-284). 
SPR sensorgrams were analyzed with the aid of Scrubber 2 
and ClampXP software (Center for Biomolecular Interac-
tions Analysis, University of Utah) (Morton TA, et al. Meth-
ods Enzymol. 1998; 295:268-294; Morton TA, et al. Anal 60 
Biochem. 1995; 227(1):176-185; Myszka D G, et al. Trends 
Biochem Sci. 1998; 23(4):149-150). Prior to analysis, all 
sensorgrams were inspected for abnormalities (i.e. baseline 
drift, air spikes, or irregular deviations) and excluded. Refer-
ence cell responses were subtracted from corresponding 
active response curves. Double-referenced curves were 
acquired by further subtracting the reference cell blank buffer 
Results 
The fitted parameters (Bmax' ka, and kd) for each knob 
peptide variant for the heterogeneous ligand model are dis-
played in Table 5. Additionally, the sensorgram plots in FIG. 
1 OA illustrate the contribution each fitted parameter set has on 
the overall combined 2-site model. For example, for GPRPF-
65 PAC (SEQ ID N0:5), the fit for the AB complex (site 1) 
encompassed a fast association rate presumably accounting 
for the large initial response, while the slower association rate 
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for the AB* complex (site 2) contributes to the slower 
response for the duration of the injection. Broadly comparing 
all the knob peptide variant parameters, the 4Pro peptides 
(i.e., GPRPAAC (SEQ ID N0:4), GPRPFPAC (SEQ ID 
N0:5), and GPRPPERC (SEQ ID N0:6)) had much faster 5 
association rates (ka1 =2.84 to 21.72xl03 M- 1 s- 1 ,ka2 =1.0l to 
1.81xl03 M- 1s- 1) than the 4Val peptides (i.e., GPRVVAAC 
(SEQ ID N0:8) and GPRVVERC (SEQ ID N0:7); ka1 =0.62 
ther indicates that GPRPFPAC (SEQ ID N0:5) interacts and 
engages the hole domains more readily than the other variants 
tested, even the gold standard GPRP (SEQ ID NO: 1) mimic 
(GPRPAAC, SEQ ID N0:4). In comparing GPRVVAAC 
(SEQ ID N0:8) to GPRVVERC (SEQ ID N0:7), the addition 
of charged residues, 6Glu and 7 Arg, decreased Kn2 from 
25.00 µM to 15.71 µM, while Km was relatively similar. 
to 1.07xl03M- 1 s- 1 , ka2=0.04 to 0.26xl03 M- 1s- 1). Example 10 
In comparing the 4Pro variants, one of the most striking 10 
differences was the nearly ten-fold increase in ka1 for 
GPRPFPAC (SEQ ID N0:5) (21.72xl03 M- 1s- 1) compared 
Molecular Dynamics Simulation Analysis 
to GPRPAAC (SEQ ID N0:4) (2.84xl03 M- 1 s- 1 s- 1 ) and 
GPRPPERC (SEQ ID N0:6) (3.22xl03 M- 1 s- 1 ); however for 
kd1 , GPRPAAC (SEQ ID N0:4) (12.83xl0-3 s- 1 ) displayed a 15 
six-fold slower rate compared to GPRPFPAC (SEQ ID N0:5) 
(81.lOxl0-3 s- 1). In contrast, for the second binding site the 
ka2 rate for GPRPFPAC (SEQ ID N0:5) (1.81xl03 M- 1 s- 1 ) 
was only moderately faster than GPRPAAC (SEQ ID N0:4) 
(1.05xl03 M- 1s- 1) and GPRPPERC (SEQ ID N0:6) (1.0lx 20 
103 M- 1s- 1), while the kd2 for GPRPFPAC (SEQ ID N0:5) 
(1.96x10-3 s- 1)wasnearlyeight-foldslowerthanGPRPAAC 
(SEQ ID N0:4) (8.95xl0-3 s- 1). These simulation results 
indicate that GPRPFPAC (SEQ ID N0:5) has a higher affinity 
Materials and Methods 
Molecular Dynamics (MD) Simulations 
Classical MD simulations were performed with five knob 
'A' peptides, GPRVVAAC (SEQ ID N0:8), GPRVVERC 
(SEQ ID N0:7), GPRPAAC (SEQ ID N0:4), GPRPPERC 
(SEQ ID N0:6), and GPRPFPAC (SEQ ID N0:5). Since the 
crystal structure of each of these peptides within the fibrin 
hole has not been determined experimentally, the initial pep-
tide structures were rendered in Swiss-PDB Viewer (Swiss 
Institute of Bioinformatics, Guex N, et al. Electrophoresis. 
1997; 18(15):2714-2723) with the backbone torsion angles of 
the first three residues constrained to an 'active' peptide con-
to the first and second binding sites and additionally dissoci- 25 
ates more slowly from the second binding site, thus translat-
ing to longer engagement in fibrinogen holes compared to the 
other variants tested. 
formation obtained from previously published fragment D 
crystal structures (PDB code: 2HPC and 2FFD, Betts L, et al. 
Journal of Thrombosis and Haemostasis. 2006; 4(5): 1139-The impact additional charged residues in the sixth and 
seventh position had on functional binding characteristics 
was also investigated by comparing GPRVVAAC (SEQ ID 
N0:8) and GPRVVERC (SEQ ID N0:7). For the association 
rates, GPRVVERC (SEQ ID N0:7) had a two-fold increase 
over GPRVVAAC (SEQ ID N0:8) in ka 1 (1.07xl03 M- 1s- 1 
vs. 0.62xl03 M- 1 s- 1 , respectively) and a six-fold increase in 
ka2 , (0.26xl03 M- 1 s- 1 vs. 0.04xl03 M- 1s-1, respectively). 
However, the dissociation rates for GPRVVERC (SEQ ID 
N0:7) were two-fold faster than GPRVVAAC (SEQ ID 
N0:8) for kd1 (57.67xl0-3 s- 1 vs 30.08xl0-3 s- 1 , respec-
tively) and four-fold faster for kd2 ( 4.07xl0-3 s- 1 vs 1.00x 
10-3 s- 1 , respectively). These results collectively imply that 
while the additional charged residues (i.e., 6Glu and 7Arg) 
may enhance the affinity of the knob peptide to the binding 
holes, it may also result in an increased rate of dissociation. 
Example 9 
Equilibrium Dissociation Constants 
Results 
Using the fitted kas and kds from the kinetic models, the 
equilibrium dissociation constants were calculated (Kns; 
Table 5). These results are also represented graphically by 
plotting the SPR binding maximum for each variant versus 
injection concentration (FIG. lOB). The lowest Kns were 
observed in the peptide variants with a 4Pro (GPRPFPAC 
(SEQ ID N0:5)<GPRPAAC (SEQ ID N0:4)<GPRPPERC 
(SEQ ID N0:6)<GPRVVERC (SEQ ID N0:7)<GPRV-
VAAC (SEQ ID N0:8)). In comparing the specific Kns for 
the each site between the 4Pro variants, Km for GPRPFPAC 
(SEQ ID N0:5) (3.73 µM) and GPRPAAC (SEQ ID N0:4) 
30 1141 ). Prior to MD simulations, the structure of each peptide 
was minimized with 10 iterations of steepest descent (500 
steps) energy minimization in vacuo. Each peptide was 
placed in the center of a water box (Visual Molecular Dynam-
ics software, Humphrey W, et al. J Mal Graph. 1996; 14(1): 
35 33-38, 27-38) supplemented with Na+ and c1- ions to achieve 
electric neutrality, mimicking experimental conditions (-340 
mOsmol/L). The models were initially minimized for 1000 
steps with the backbone atoms fixed, followed by 1000 steps 
of minimization with harmonic restraints on the alpha carbon 
40 atoms. After energy minimization, each system was heated to 
31 OK over a period of 20 ps with harmonic restraints on the 
alpha carbons. Next, with the restraints still active, each sys-
tem was equilibrated at constant temperature (31 OK) and 
pressure (1 atm) for 100 ps. The restraints were then removed, 
45 and the equilibration was continued for 200 ps. The produc-
tion runs were carried out for 10 ns under constant tempera-
ture and pressure conditions, i.e. the NPT ensemble. Tem-
perature was maintained at 310K, pressure at 1 atm. Short-
range non-bonded interactions were cut off at a distance of 12 
50 A with a switching function between 10 and 12 A. The par-
ticle mesh Ewald method was used to compute electrostatics 
(Darden T, et al. Journal of Chemical Physics. 1993; 98(12): 
10089-10092). All bonds involving hydrogen atoms were 
constrained using the SHAKE algorithm (Ryckaert JP, et al. 
55 Journal of Computational Physics. 1977; 23(3):327-341), 
which allowed for an integration time step of 2fs. All simu-
lations were performed with NAMD Version 2.6 (Theoretical 
and Computational Biophysics Group at University of Illinois 
at Urbana-Champaign, Phillips JC, et al. Journal ofCompu-
60 tational Chemistry. 2005; 26(16): 1781-1802) using the 
CHARMM22 force field parameter set (MacKerell AD, et al. 
Journal of Physical Chemistry B. 1998; 102(18):3586-3616). 
( 4.53 µM) was significantly lower than GPRPPERC (SEQ ID 
N0:6) (18.23 µM). However, for the second site, the Km 
values for GPRPFPAC (SEQ ID N0:5) (1.08 µM) and GPRP- 65 
PERC (SEQ ID N0:6) (2.93 µM) were significantly lower 
than GPRPAAC (SEQ ID N0:4) (8.52 µM). This result fur-
Clustering Analysis 
A hierarchical cluster analysis was performed on the tra-
jectory data from each peptide MD simulation. A trajectory 
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for clustering was obtained by taking every 1 OOth frame (100 
ps interval) from a 10 ns production run. Next, we calculated 
the root mean squared deviation (RMSD) between every 
frame in the trajectory to generate a dissimilarity matrix. 
52 
TABLE6 
Root mean sguared deviation (RMSD) 
Population Backbone RMSD Total RMSD 
RMSD was calculated based on the backbone atoms after 5 Peptide (%of total) (A)* (A)* 
~~~~~~~~~~~~~~~~~~~~~~-
38% 0.799 4.564 
27% 0.803 4.709 
60% 0.594 4.615 
17% .0655 4.802 
optimal superposition. The agnes function in the cluster pack-
age supplied with the R statistical software package was used 
to construct a hierarchy of clusterings from the dissimilarity 
matrix. The clusters were visualized in VMD using the Clus-
ter plugin. Based on the resulting dendrograms generated 10 
from the cluster analysis (FIG. 13), representative trajectory 
conformations from the two most populated cluster group-
ings at the third level were used to compare both conforma-
tional and electrostatic properties between each peptide. 15 
GP RP AA C 
(SEQ ID NO: 4) 
GPRPFPAC 
(SEQ ID NO: 5) 
GPRPPERC 
(SEQ ID NO: 6) 
GPRVVERC 
(SEQ ID NO: 7) 
GPRVVAAC 
(SEQ ID NO: 8) 
43% 
31% 
59% 
23% 
48% 
28% 
0.862 4.896 
0.623 4.894 
0.629 5.042 
0.834 5.251 
1.546 5.437 
0.717 4.757 
Structure/Conformation and Electrostatic Properties 
Comparisons 
For structural/conformational comparison, representative 
conformations from the top two populated clusters were 
superimposed onto either GPRP ((SEQ ID NO:l) or GPRV 
(SEQ ID N0:2) peptides in an 'active' conformation within 
hole 'a' as obtained from previous published fragment D 
crystal structures (PDB code: 2HPC and2FFD, respectively); 
GPRPxxx (SEQ ID N0:26) peptides were compared to 
'active' GPRP (SEQ ID NO:l) and GPRVxxx (SEQ ID 
N0:27) peptides were compared to 'active' GPRV (SEQ ID 
N0:2). After least-squares superpositioning the first three 
residues of each conformation along the backbone, the 
RMSD of the first three residues was calculated with the 
'active' GPRP (SEQ ID NO:l) or GPRV (SEQ ID N0:2) as 
the reference; both the backbone and total atom RMSDs were 
calculated. For electrostatic comparisons, electrostatic poten-
tial surface maps for representative conformations from the 
top populated cluster group for each peptide were generated 
with Adaptive Poisson-Boltzmann Solver (APBS) using the 
CHARMM22 force field parameter set (Baker N A, et al. P 
Natl Acad Sci USA. 2001; 98(18): 10037-10041). 
Results 
MD simulations were performed to compare conforma-
tional structures of the peptides immersed in an aqueous 
environment prior to engagement with fibrin holes. Due to the 
large amount of data (i.e. conformations) in a 10 ns MD 
trajectory, a hierarchical clustering method was used to select 
a smaller set of conformations representative of the entire MD 
trajectory (FIG.13). From this cluster analysis, representative 
conformations from the two most populated clusters for each 
peptide were used to compare structural features between 
experimental peptides. The representative conformations for 
each peptide were then superimposed on either 'active' GPRP 
(SEQ ID NO: 1) or GPRV (SEQ ID N0:2) peptides obtained 
from fragment D crystal structures (PDB code: 2HPC and 
2FFD, respectively). The superposition of simulation confor-
mations with 'active' conformation was evaluated by calcu-
lating the RMSD for atoms (backbone and all atoms) from the 
first three residues of the simulation conformations in refer-
ence to the known active conformations. The lower the 
RMSD, the better the alignment to the reference point. Rank-
ing the peptides from lowest to highest weighted average 
RMSD along the backbone was GPRPFPAC (SEQ ID N0:5) 
(0.607 A)<GPRVVERC (SEQ ID N0:7) (0.670 A)<GPRP-
PERC (SEQ ID N0:6) (0.761 A)<GPRPAAC (SEQ ID 
N0:4) (0.801 A)<GPRVVAAC (SEQ ID N0:8) (1.241 A) 
(Table 6). 
It appears that the Pro-Phe-Pro residues in GPRPFPAC 
(SEQ ID N0:5) help stabilize the backbone of the first three 
residues to a conformation similar to 'active' GPRP (SEQ ID 
20 
NO:l). Similarly, while GPRVVERC (SEQ ID N0:7) and 
GPRPPERC (SEQ ID N0:6) were chosen to investigate the 
alterations in electrostatic charge, a salt bridge developed 
between the 3Arg and 6Glu side chains potentially stabilizing 
the backbone. The RMSD of all the atoms (i.e. backbone and 
25 side chain atoms) in the first three residues were also calcu-
lated; here, the weighted average RMSD ranking from lowest 
to highest was GPRPFPAC (SEQ ID N0:5) (4.656 
A)<GPRPAAC (SEQ ID N0:4) ( 4.657 A)<GPRPPERC 
(SEQ ID N0:6) (4.895 A)<GPRVVERC (SEQ ID N0:7) 
30 (5.101 A)<GPRVVAAC (SEQ ID N0:8) (5.186 A). This 
RMSD ranking inversely correlated with the experimental 
binding affinity data (i.e. lower RMSD, higher binding affin-
ity). Considering this correlation, the orientation of the side 
chain groups was evaluated in comparison to the 'active' 
35 conformation, particularly the orientation of 3Arg, which is 
required for binding of fibrin holes. Conventional terminol-
ogy for torsional side chain angle defines Xi as the angle 
between N,-Ca,-C13,-CY'' (Chandrasekaran R, et al. Int J Pro-
tein Res. 1970; 2(4):223-233); the three common rotamer 
40 classifications are gauche- (0 to 120°), trans (120 to 240°), 
and gauche+ (-120to 0°) (Ponder JW, eta!. Mo!. Biol. 1987; 
193( 4):775-791). In the 'active' conformation for both GPRP 
(SEQ ID NO: 1) and GPRV (SEQ ID N0:2), the 3Arg Xi angle 
is in a gauche+ conformation. However, in assessing the X 1 
45 angle of the 3Arg side chain for GPRPAAC (SEQ ID N0:4) 
and GPRVV AAC (SEQ ID NO: 8), it was noted that the angle 
was predominantly in a trans conformation during the simu-
lation (i.e. pointing toward the carboxyl-terminus of the 
sequence). In contrast, the 3Arg group in GPRPFPAC (SEQ 
50 ID N0:5) was mobile, but predominantly in the gauche+ 
conformation and rarely the trans conformation. The bulky 
side chain on 5Phe stericly may hinder electrostatic interac-
tions between 3Arg and the C-terminus as observed in GPRV-
VAAC (SEQ ID N0:8) and GPRPAAC (SEQ ID N0:4). 
55 Additionally, the salt bridge formation between 3Arg and 
6Glu in GPRVVERC (SEQ ID N0:7) and GPRPPERC (SEQ 
ID N0:6) appeared to stabilize the 3Arg side chain in the 
gauche+ conformation. Collectively, these observations sug-
gest that the 3Arg rotameric classifications depended on 
60 properties of the downstream residues. 
As previously mentioned, knob:hole interactions are 
driven by electrostatic interactions. Therefore, electrostatic 
potential surface maps were generated to display the charge 
distributions for each peptide variant. The 'active' conforma-
65 tion of GPRV (SEQ ID N0:2) has a noticeably positively 
charged N-terminus generated by lGly and 3Arg; GPRP 
(SEQ ID NO: 1) has similar structure/map properties. For the 
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peptide variants, it was noted that the electrostatic mapping 
was directly related to the 3Arg side chain rotamer classifi-
cation, where the gauche+ 3Arg conformations maintained 
the concentrated positive charge around 1 Gly and 3Arg (i.e., 
GPRPFPAC, SEQ ID NO: 5). However, with 3Arg in the trans 5 
conformation (i.e., GPRPAAC (SEQ ID N0:6) and GPRV-
VAAC (SEQ ID N0:8)), the positive charge was more 
broadly distributed from the N-terminus across to the C-ter-
minus. The addition of -ERC in the sixth through eighth 
residues resulted in two alterations. First, while the salt bridge 10 
between 3Arg and 6Glu stabilized 3Arg in the gauche+ con-
formation providing a concentrated positive charge at the 
N-terminus, the presence of 6Glu contributed a slightly nega-
tive charge near 3A. Secondly, the additional Arg residue in 
the seventh position redistributed the positive charge more 15 
broadly across the peptide chain. Collectively, these molecu-
lar dynamics simulations and subsequent analyses provided 
snapshots at the molecular level into potential intra-chain 
interactions that occur in aqueous environments and may 
contribute to the initial binding interactions with fibrin holes. 20 
54 
ization compared to the unconjugated peptide at the same 
concentration (below the active concentration of free knob, 
i.e. 400 µM) while the unconjugated PEG had no effect (FIG. 
15). In a follow-on experiment, fibrinogen was preincubated 
with knob-PEG conjugates (PEG, PEG2 , and PEG4 ) for 1 
hour and turbidity monitored (FIG. 15B). Immediately fol-
lowing the preincubation thrombin was added to the solution 
and polymerization monitored. The results indicate that the 
multifunctional knob-PEG conjugates support some type of 
polymerization, presumably due to knob-pocket interactions, 
however, upon addition of thrombin the further polymeriza-
tion (turbidity) was not observed. PEG 1 -knob inhibited poly-
merization to 10%. 
Example 13 
Altered Fibrin Structure with Sub-Inhibiting 
Concentrations of PEGylated Fibrin Knob Peptides 
Results 
Example 11 
Maleimide-Activated Peg Conjugated to Knob 
Peptides Via a C-Terminal Cysteine 
Polymerization rate (turbidity curves), percent clottable 
protein, fiber structure (SEM), and viscoelastic properties of 
fibrin polymerized in the presence or absence of PEGylated-
25 GPRPFPAC (5 kDa linear PEG chain, SED ID N0:53) at a 
1: 1 molar ratio were evaluated. 
Results 
GPRPAAC (SEQ ID N0:4) was used as the model knob 
peptide sequence to establish feasibility for this set of experi- 30 
ments. Maleimide-activated PEG and a molar excess of syn-
thesized knob peptide, GPRPAAC (SEQ ID N0:4) or 
GPSPAAC (SEQ ID N0:9, negative control), were reacted in 
a phosphate-buffered conjugation buffer at room tempera-
ture. To maximize the conjugation of PEG to peptide while 35 
minimizing the loss of peptide, several different reactant 
(sulfhydryl-to-maleimide) molar ratios were tested. The reac-
tion mix was subsequently dialyzed into water to remove salt 
and unreacted peptide. A representative set of conjugation 
reactions was conducted using the three varieties of PEG 40 
( 1-arm, 2-arm, 4-arm) that would be used in the development 
ofSA3. PEGylated peptide products were then characterized 
for PEG concentration using a colorimetric assay based on 
the partitioning of ferrothiocyanate in a biphasic system 
(Barker T H, et al. Anal Biochem 2001 March; 290(2):382- 45 
385; Nag A, et al. Anal Biochem 1996 Jun. 1; 237(2):224-
231). The CBQCA assay (Invitrogen, Carlsbad, Calif.) was 
used to determine peptide concentration and the molar ratio 
Turbidity and Percent Clottability 
The turbidity curves upon initiating thrombin-activated 
polymerization and the amount of soluble protein remaining 
in the clot liquor after polymerization (percent clottable pro-
tein) were evaluated. All assays were performed with 1 mg/ml 
fibrinogen, 1 U/ml thrombin, 1 U/mL factor XIIIa, and 5 mM 
CaC12 ; all PEG conjugates were tested at a 1: 1 molar ratio. A 
lower maximum absorbance turbidity value was observed, 
indicating thinner fibrin fibers and/or reduced clottable pro-
tein (FIG. 16A). However, the percentage of clottable protein 
did not change for the control GPSPFPAC-PEG (SEQ ID 
N0:18) and only decreased from -95% to 92% in the pres-
ence ofGPRPFPAC-PEG (SEQ ID N0:5) (FIG. 16B). These 
results indicated that this minor but significant change altered 
the fibrin fiber microstructure. 
Fibrin Structure 
Fibrin clots were polymerized in the presence or absence of 
PEGylated knob peptides at a 1: 1 molar ratio. The clots were 
then fixed, dehydrated with a series of acetone-water solu-of peptide to PEG, reflecting the efficiency of the conjugation 
reaction (FIG. 14). 50 tions and critical point drying (acetone-C02 exchange). 
Example 12 
Dehydrated samples were then mounted on aluminum stubs 
and sputter coated with gold-palladium. Micro structure of the 
samples were then examined via scanning electron micros-
copy (Zeiss Ultra SEM) at 15,000x magnification. A more Knob-PEG Conjugates are Capable of Modifying 
Fibrin Polymerization in a Dose Dependent Mamier 
Results 
55 porous structure with thinner fibers were observed with 
GPRPFPAC-PEG (SEQ ID N0:5) compared to control pep-
tide conjugate (GPSPFPAC-PEG, SEQ ID N0:18) and no 
peptide control. 
Fibrin polymerization and plasmin degradation assays 
were used to evaluate the efficacy of the PEG-peptide conju- 60 
gates generated above. Fibrin polymerization was induced by 
the addition of a thrombin solution containing the monofunc-
tional PEG-GPRP conjugates (SEQ ID NO: 1) product or the 
unmodified knob and polymerization monitored over an hour 
by measuring the absorbance at 350 nm (clot turbidity, FIG. 65 
14 (a)). The PEG-GPRP (SEQ ID NO:l) conjugates were 
more effective in altering the progression of fibrin polymer-
Example 14 
Results 
Peptide variants were based on the thrombin cleaved N-ter-
minus offibrinAa chains (A-knob; GPRVVERHQS, SEQ ID 
N0:40). It is shown that the 1st, 2nd, and 3rd residues are 
critical for binding to fibrinogen pockets and at high enough 
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concentrations the peptides compete for pockets and inhibit 
polymerization. It is also shown that the knob peptide, 
GPRPFPAC (SEQ ID N0:5), binds with higher affinity to 
fibrin(ogen) pockets than the gold standard knob peptide, 
GPRP (SEQ ID NO:l). Additionally, using molecular mod-
eling, key structural and electrostatic properties of GPRPF-
PAC (SEQ ID N0:5) that enhanced the binding affinity to 
fibrinogen pockets were identified. Specifically, the 5Phe 
group appeared to help maintain the 3Arg side chain in the 
active conformation to maintain a dense positive charge at the 10 
N-terminal. In contrast, the low binding peptide GPRVV AAC 
(SEQ ID NO:S) had a broader positive charge distribution at 
the N-terminal. 
The higher affinity knob peptide, GPRPFPAC (SEQ ID 
N0:5) may therefore inhibit fibrin polymerization more effi- 15 
ciently than the lower affinity knob peptides GPRPAAC 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 40 
<210> SEQ ID NO 1 
<211> LENGTH, 4 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 1 
Gly Pro Arg Pro 
1 
<210> SEQ ID NO 2 
<211> LENGTH, 4 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 2 
Gly Pro Arg Val 
1 
<210> SEQ ID NO 3 
<211> LENGTH, 4 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 3 
Gly His Arg Pro 
1 
<210> SEQ ID NO 4 
<211> LENGTH, 7 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 4 
Gly Pro Arg Pro Ala Ala Cys 
1 5 
<210> SEQ ID NO 5 
<211> LENGTH, 8 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 5 
Gly Pro Arg Pro Phe Pro Ala Cys 
1 5 
56 
(SEQ ID N0:4) and GPRPPERC (SEQ ID N0:6). Therefore, 
percent clottable protein was measured via protein assay after 
1 hr of thrombin-induced polymerization in presence or 
absence of fibrin knob peptides. Results from these percent 
clottable protein assays indicated that at the same concentra-
tion, GPRPFPAC (SEQ ID N0:5) inhibits fibrin assembly 
(i.e. clot formation) to a greater extent than GPRPAAC (SEQ 
ID N0:4) and GPRPPERC (SEQ ID N0:6) (FIG. 17). 
Unless defined otherwise, all technical and scientific terms 
used herein have the same meanings as commonly under-
stood by one of skill in the art to which the disclosed invention 
belongs. Those skilled in the art will recognize, or be able to 
ascertain using no more than routine experimentation, many 
equivalents to the specific embodiments of the invention 
described herein. Such equivalents are intended to be encom-
passed by the following claims. 
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-continued 
<210> SEQ ID NO 
<211> LENGTH, 8 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 
Gly Pro Arg Pro Pro Glu Arg Cys 
1 5 
<210> SEQ ID NO 7 
<211> LENGTH, 8 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 7 
Gly Pro Arg Val Val Glu Arg Cys 
1 5 
<210> SEQ ID NO 8 
<211> LENGTH, 8 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 8 
Gly Pro Arg Val Val Ala Ala Cys 
1 5 
<210> SEQ ID NO 9 
<211> LENGTH, 7 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 9 
Gly Pro Ser Pro Ala Ala Cys 
1 5 
<210> SEQ ID NO 10 
<211> LENGTH, 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 10 
Gly Pro Arg Pro Ala Ala 
1 5 
<210> SEQ ID NO 11 
<211> LENGTH, 4 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 11 
Gly Ser Pro Glu 
1 
<210> SEQ ID NO 12 
<211> LENGTH, 30 
<212> TYPE, DNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 12 
actggtcgac tgggtcttga ttccccaact 30 
<210> SEQ ID NO 13 
<211> LENGTH, 40 
<212> TYPE, DNA 
59 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 13 
actggtcgac tcagcaacca cctgttcggt aattaatgga 
<210> SEQ ID NO 14 
<211> LENGTH, 8 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 14 
Leu Val Pro Arg Gly Ser Pro Glu 
1 5 
<210> SEQ ID NO 15 
<211> LENGTH, 8 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 15 
Leu Val Pro Arg Gly Pro Arg Val 
1 5 
<210> SEQ ID NO 16 
<211> LENGTH, 8 
<212> TYPE, PRT 
<213> ORGANISM, Homo 
<400> SEQUENCE, 16 
Leu Val Pro Arg Gly 
1 5 
<210> SEQ ID NO 17 
<211> LENGTH, 8 
<212> TYPE, PRT 
<213> ORGANISM, Homo 
<400> SEQUENCE, 17 
Leu Val Pro Arg Gly 
1 5 
<210> SEQ ID NO 18 
<211> LENGTH, 8 
<212> TYPE, PRT 
<213> ORGANISM, Homo 
<400> SEQUENCE, 18 
Gly Pro Ser Pro Phe 
1 5 
<210> SEQ ID NO 19 
<211> LENGTH, 4 
<212> TYPE, PRT 
sapiens 
Pro Arg 
sapiens 
His Arg 
sapiens 
Pro Ala 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 19 
Gly Pro Ser Pro 
1 
<210> SEQ ID NO 20 
<211> LENGTH, 4 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (2) .. (2) 
Pro 
Pro 
Cys 
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<223> OTHER INFORMATION, Xaa is any amino acid 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (4) .. (4) 
<223> OTHER INFORMATION, Xaa is any amino acid 
<400> SEQUENCE, 20 
Gly Xaa Arg Xaa 
1 
<210> SEQ ID NO 
<211> LENGTH, 4 
<212> TYPE, PRT 
21 
<213> ORGANISM, Homo sapiens 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (2) .. (2) 
<223> OTHER INFORMATION, Xaa 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (4) .. (4) 
<223> OTHER INFORMATION, 
<400> SEQUENCE, 21 
Gly Xaa Arg Xaa 
1 
<210> SEQ ID NO 
<211> LENGTH, 5 
<212> TYPE, PRT 
22 
Xaa 
<213> ORGANISM, Homo sapiens 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (5) .. (5) 
<223> OTHER INFORMATION, Xaa 
<400> SEQUENCE, 22 
Gly Pro Arg Pro Xaa 
1 5 
<210> SEQ ID NO 23 
<211> LENGTH, 5 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (5) .. (5) 
<223> OTHER INFORMATION, Xaa 
<400> SEQUENCE, 23 
Gly Pro Arg Val Xaa 
1 5 
<210> SEQ ID NO 24 
<211> LENGTH, 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, ( 5) .. (6) 
<223> OTHER INFORMATION, 
<400> SEQUENCE, 24 
Gly Pro Arg Pro Xaa Xaa 
1 5 
<210> SEQ ID NO 25 
<211> LENGTH, 
<212> TYPE, PRT 
Xaa 
<213> ORGANISM, Homo sapiens 
is any amino acid 
is any amino acid 
is any amino acid 
is any amino acid 
is any amino acid 
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<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (5) .. (6) 
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<223> OTHER INFORMATION, Xaa is any amino acid 
<400> SEQUENCE, 25 
Gly Pro Arg Val Xaa Xaa 
1 5 
<210> SEQ ID NO 26 
<211> LENGTH, 7 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (5) .. (7) 
<223> OTHER INFORMATION, Xaa is any amino acid 
<400> SEQUENCE, 26 
Gly Pro Arg Pro Xaa Xaa Xaa 
1 5 
<210> SEQ ID NO 27 
<211> LENGTH, 7 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (5) .. (7) 
<223> OTHER INFORMATION, Xaa is any amino acid 
<400> SEQUENCE, 27 
Gly Pro Arg Val Xaa Xaa Xaa 
1 5 
<210> SEQ ID NO 28 
<211> LENGTH, 8 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (5) .. (8) 
<223> OTHER INFORMATION, Xaa is any amino acid 
<400> SEQUENCE, 28 
Gly Pro Arg Pro Xaa Xaa Xaa Xaa 
1 5 
<210> SEQ ID NO 29 
<211> LENGTH, 8 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (5) .. (8) 
<223> OTHER INFORMATION, Xaa is any amino acid 
<400> SEQUENCE, 29 
Gly Pro Arg Val Xaa Xaa Xaa Xaa 
1 5 
<210> SEQ ID NO 30 
<211> LENGTH, 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (4) .. (7) 
<223> OTHER INFORMATION, Xaa is any amino acid 
64 
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<400> SEQUENCE, 30 
Gly Pro Arg Xaa Xaa Xaa 
1 5 
<210> SEQ ID NO 31 
<211> LENGTH, 7 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, ( 6) .. (7) 
<223> OTHER INFORMATION, Xaa 
<400> SEQUENCE, 31 
Gly Pro Arg Pro Phe Xaa Xaa 
1 5 
<210> SEQ ID NO 32 
<211> LENGTH, 7 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<220> FEATURE, 
<221> NAME/KEY, misc 
<222> LOCATION, (6) .. (7) 
US 8,513,380 B2 
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is any amino acid 
<223> OTHER INFORMATION, Xaa is any amino acid 
<400> SEQUENCE, 32 
Gly Pro Arg Val Phe Xaa Xaa 
1 5 
<210> SEQ ID NO 33 
<211> LENGTH, 12 
<212> TYPE, DNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 33 
ggatccccgg aa 
<210> SEQ ID NO 34 
<211> LENGTH, 12 
<212> TYPE, DNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 34 
ggaccccggg ta 
<210> SEQ ID NO 35 
<211> LENGTH, 12 
<212> TYPE, DNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 35 
ggaccccggc ca 
<210> SEQ ID NO 36 
<211> LENGTH, 12 
<212> TYPE, DNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 36 
ggacaccggc ca 
<210> SEQ ID NO 37 
<211> LENGTH, 5 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
66 
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-continued 
<400> SEQUENCE, 37 
Pro His Ser Arg Asn 
1 5 
<210> SEQ ID NO 38 
<211> LENGTH, 5 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (4) .. (4) 
<223> OTHER INFORMATION, Xaa is any amino acid except Pro 
<400> SEQUENCE, 38 
Val Pro Gly Xaa Gly 
1 5 
<210> SEQ ID NO 39 
<211> LENGTH, 5 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 39 
Val Pro Gly Val Gly 
1 5 
<210> SEQ ID NO 40 
<211> LENGTH, 10 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 40 
Gly Pro Arg Val Val Glu Arg His Gln Ser 
1 5 10 
I claim: 
1. A recombinant fusion protein, comprising a fibrin knob 
peptide selected from the group consisting of SEQ ID NOs: 
5-8 at the N-terminus of the fusion protein, wherein the fusion 
protein binds fibrin. 
2. The recombinant fusion protein of claim 1, further com-
prising a bioactive polypeptide that promotes wound healing 
or fibrinolysis. 
3. The recombinant fusion protein of claim 2, wherein the 
bioactive polypeptide is a growth factor, cytokine, adhesion 
domain, anti-adhesion domain, immunomodulatory domain, 
protein-binding domain, nucleic acid-binding domain, 
polysaccharide-binding domain, virus-binding domain, cyto-
toxic domain, enzymatically active domain, protease inhibi-
40 tor, serum protein, or fragment thereof, that binds its receptor. 
4. The recombinant fusion protein of claim 3, wherein the 
bioactive polypeptide is tissue plasminogen activator (tPA), 
or a fragment thereof that promotes fibrinolysis. 
5. The recombinant fusion protein of claim 1, further com-
45 prising an inert protein that sterically hinders fibrin polymer-
ization when the fusion protein binds fibrin. 
6. The recombinant fusion protein of claim 5, wherein the 
inert protein is human serum albumin. 
7. The recombinant fusion protein of claim 1, conjugated to 
50 a polyethylene glycol. 
* * * * * 
